University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2012

Signaling by Non-Canonical Receptor Tyrosine Kinases ERBB3
and RYK
Fumin Shi
University of Pennsylvania, fumin.shi@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, Biophysics Commons, and the Cell Biology Commons

Recommended Citation
Shi, Fumin, "Signaling by Non-Canonical Receptor Tyrosine Kinases ERBB3 and RYK" (2012). Publicly
Accessible Penn Dissertations. 699.
https://repository.upenn.edu/edissertations/699

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/699
For more information, please contact repository@pobox.upenn.edu.

Signaling by Non-Canonical Receptor Tyrosine Kinases ERBB3 and RYK
Abstract
Signaling by receptor tyrosine kinases (RTKs) typically involves binding of extracellular ligands and
subsequent activation of intracellular kinase domain, which in turn mediates autophosphorylation and
downstream signal transduction. However, several RTKs, such as ErbB3 (HER3) and Ryk/Derailed, lack key
conserved (and catalytically important) residues in their intracellular kinase domain, and are thought to be
inactive `pseudo'-kinases. Much less is known regarding how these receptor tyrosine `pseudo'-kinases
mediate transmembrane signaling. The work described in this dissertation attempts to understand the
non-canonical signaling by ErbB3 and Ryk/Derailed using a combination of biophysical, biochemical and
cell biology methods. ErbB3 is one of four members of the human epidermal growth factor receptor
(EGFR) family. ErbB3 signals primarily by heterodimerizing with ErbB2 (HER2) and mediates resistance of
tumor cells to EGFR/ErbB2-targeted therapeutics. We have investigated the role of ErbB3 `pseudo'-kinase
domain in its signaling. In vitro enzymology study shows that, despite the sequence alterations, ErbB3
kinase domain binds ATP with high affinity and possesses weak kinase activity to transautophosphorylate its intracellular region. We also describe a crystal structure of ErbB3 kinase, which
resembles the inactive EGFR and ErbB4 kinase domains. Whereas mutations that destabilize this
configuration activate EGFR and ErbB4 (and promote EGFR-dependent lung cancers), a similar mutation
conversely compromises ErbB3's ability to activate downstream Akt signaling in our cellular studies.
These findings suggest that ErbB3 kinase may be crucial for signaling and could represent an important
therapeutic target. Ryk and its Drosophila homolog Derailed (Drl) contain an extracellular Wnt Inhibitory
Factor (WIF) domain and participate in non-canonical Wnt signaling. We attempt to understand, for the
first time, the molecular mechanism of Ryk/Drl-Wnt interaction using Drl as a model system. We show
that Drl binds directly to Drosophila Wnt5 (DWnt5) with submicromolar affinity using surface plasmon
resonance (SPR). X-ray crystallography study has identified a conserved binding site of Drl for DWnt5.
Mutating this site abolishes DWnt5 binding by Drl. This study serves as a starting point for our
understanding of Wnt signaling by Ryk/Drl at a molecular level.
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ABSTRACT
SIGNALING BY NON-CANONICAL RECEPTOR TYROSINE KINASES
ERBB3 AND RYK
Fumin Shi
Mark A. Lemmon
Signaling by receptor tyrosine kinases (RTKs) typically involves binding of
extracellular ligands and subsequent activation of intracellular kinase domain, which in
turn mediates autophosphorylation and downstream signal transduction. However,
several RTKs, such as ErbB3 (HER3) and Ryk/Derailed, lack key conserved (and
catalytically important) residues in their intracellular kinase domain, and are thought to
be inactive ‗pseudo‘-kinases. Much less is known regarding how these receptor tyrosine
‗pseudo‘-kinases mediate transmembrane signaling. The work described in this
dissertation attempts to understand the non-canonical signaling by ErbB3 and
Ryk/Derailed using a combination of biophysical, biochemical and cell biology methods.
ErbB3 is one of four members of the human epidermal growth factor receptor
(EGFR) family. ErbB3 signals primarily by heterodimerizing with ErbB2 (HER2) and
mediates resistance of tumor cells to EGFR/ErbB2-targeted therapeutics. We have
investigated the role of ErbB3 ‗pseudo‘-kinase domain in its signaling. In vitro
enzymology study shows that, despite the sequence alterations, ErbB3 kinase domain
binds ATP with high affinity and possesses weak kinase activity to transautophosphorylate its intracellular region. We also describe a crystal structure of ErbB3
kinase, which resembles the inactive EGFR and ErbB4 kinase domains. Whereas
iii

mutations that destabilize this configuration activate EGFR and ErbB4 (and promote
EGFR-dependent lung cancers), a similar mutation conversely compromises ErbB3‘s
ability to activate downstream Akt signaling in our cellular studies. These findings
suggest that ErbB3 kinase may be crucial for signaling and could represent an important
therapeutic target.
Ryk and its Drosophila homolog Derailed (Drl) contain an extracellular Wnt
Inhibitory Factor (WIF) domain and participate in non-canonical Wnt signaling. We
attempt to understand, for the first time, the molecular mechanism of Ryk/Drl-Wnt
interaction using Drl as a model system. We show that Drl binds directly to Drosophila
Wnt5 (DWnt5) with submicromolar affinity using surface plasmon resonance (SPR). Xray crystallography study has identified a conserved binding site of Drl for DWnt5.
Mutating this site abolishes DWnt5 binding by Drl. This study serves as a starting point
for our understanding of Wnt signaling by Ryk/Drl at a molecular level.
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Chapter 1
Characterization of ErbB3 Tyrosine Kinase Domain

1

1.1

Introduction to Receptor Tyrosine Kinase ErbB3

1.1.1

Overview of ErbB Family Receptor Tyrosine Kinases

Human ErbB receptor tyrosine kinases (RTKs), including ErbB1 (EGFR), ErbB2 (HER2),
ErbB3 (HER3) and ErbB4 (HER4), are type I transmembrane proteins that mediate
cellular responses to an array of extracellular ligands (Yarden and Sliwkowski 2001;
Hynes and MacDonald 2009). Each receptor contains an extracellular ligand binding
region, a single transmembrane helix, and an intracellular tyrosine kinase domain (TKD)
that is flanked by juxtamembrane and C-terminal regulatory regions (Baselga and Swain
2009; Hynes and MacDonald 2009) (Figure 1.1, left). Upon ligand binding to the
extracellular region, ErbB receptors undergo homo- or hetero- dimerization (Lemmon
2009), bringing their intracellular TKDs close to each other. The proximity of the
intracellular domains (ICD) induces allosteric trans-activation of enzymatic activity,
mediating the phosphoryl transfer of ATP γ-PO4 to the side chain of multiple tyrosines on
the receptor‘s C-tail (Zhang, Gureasko et al. 2006; Jura, Endres et al. 2009; Red Brewer,
Choi et al. 2009). Phosphorylation of tyrosines creates docking sites for recruitment of
various signaling molecules, which activates downstream signaling cascades (such as
MAPK and Akt pathways) and ultimately triggers cell proliferation and survival (Yarden
and Sliwkowski 2001) (Figure 1.1, right). In a pathological setting, aberrant ErbB
signaling via either ErbB protein overexpression or mutation plays an important
oncogenic driver role in the development of various cancers.

2

Figure 1.1: Scheme of ligand induced ErbB activation (shown in the figure is signaling of the ErbB2/ErbB3
heterodimer). ECD: extracellular domain; TM: transmembrane domain; JM: juxtamembrane domain; TKD:
tyrosine kinase domain. Grey circles (Y): tyrosine residues; Red circles (pY): phosphor-tyrosines; Orange
circles (L): ligand.

3

1.1.2

Introduction to ErbB3 Signaling

ErbB3 (HER3) stands out among the four mammalian ErbB receptors due to two special
properties. Firstly, it is the only ErbB protein that contains an atypical kinase domain.
When first cloned (Kraus, Issing et al. 1989; Plowman, Whitney et al. 1990), it was noted
that ErbB3 contains amino acid substitutions at two particular sites that are highly
conserved in other known kinases (Hanks, Quinn et al. 1988). Since these two residues
are involved in maintaining the active conformation and mediating the phosphoryl
transfer reaction, the ErbB3 kinase was suggested to be catalytically defective, and some
evidence was reported to this effect (to be discussed further in the following sections)
(Citri, Skaria et al. 2003).
Secondly, binding of neuregulin ligands to ErbB3 fails to induce ErbB3 homodimerization, and can only induce the formation of heterodimers between ErbB3 and
other ErbBs (Ferguson, Darling et al. 2000; Citri, Skaria et al. 2003; Berger, Mendrola et
al. 2004). Mixing neuregulin1β (Nrg1β) with recombinant ErbB3 extracellular domain
protein failed to induce homodimerization of the latter (monitored by analytical ultracentrifugation) (Ferguson, Darling et al. 2000). Using an ErbB3 ECD/EGFR ICD
chimeric protein, Berger et al. also showed that neuregulin cannot stimulate
autophosphorylation of this chimeric protein (or downstream signaling when it is
expressed in Drosophila S2 cells), unless ErbB2 protein is also expressed in the same cell
(allowing heterodimerization). In contrast, neuregulin induces a robust signaling response
in S2 cells expressing ErbB4 alone (Berger, Mendrola et al. 2004).
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Among all ErbB heterodimers that ErbB3 can form, the ErbB2/ErbB3
heterodimer is generally considered to be the most potent mitogenic signaling complex in
the ErbB receptor network (Citri, Skaria et al. 2003; Holbro, Beerli et al. 2003). In cells
that contain only these two ErbB receptors, both ErbB2 and ErbB3 are extensively
tyrosine phosphorylated upon neuregulin stimulation (Riese, van Raaij et al. 1995). Due
to the presence of multiple C-tail phosphotyrosine binding sites for the p85 subunit of
PI3K, ErbB3 is highly effective in activating the PI3K-Akt pathway that leads to cell
survival and proliferation (Prigent and Gullick 1994; Soltoff, Carraway et al. 1994;
Hellyer, Cheng et al. 1998), whereas ErbB2 is mainly responsible for activating the
MAPK pathway through Grb2/Sos recruitment (Figure 1.1). When ErbB signaling is
activated abberantly, cancer results. The ErbB2/ErbB3 heterodimer has been proposed as
an ―oncogenic unit‖ due to its potency in eliciting mitogenic and transforming signals
(Holbro, Beerli et al. 2003). Tumor mice models using transplantation of ErbB
transfected NIH-3T3 cells have shown that overexpression of ErbB2/ErbB3 causes the
most aggressive tumor growth compared with other ErbB combinations (Alaoui-Jamali,
Song et al. 2003).
1.1.3

ErbB3 in Cancer Development and Corresponding Therapeutics

Numerous studies have demonstrated an important role for aberrant ErbB3 signaling in
various cancers, including breast (Holbro, Beerli et al. 2003; Lee-Hoeflich, Crocker et al.
2008), prostate (Soler, Mancini et al. 2009), lung (Engelman, Janne et al. 2005), ovarian,
colon and gastric cancers (Sithanandam and Anderson 2008).

5

The role of ErbB3 is best characterized in breast cancer. Data from in vitro and
mouse models, plus clinical studies in humans, all argue that the ErbB2/ErbB3
heterodimer drives breast cancer progression (reviewed in (Hamburger 2008; LeeHoeflich, Crocker et al. 2008)). Overexpression of ErbB2 and/or ErbB3 in breast cancer
has been reported to correlate with poor prognosis (Travis, Pinder et al. 1996; Ferretti,
Felici et al. 2007), whereas knockdown of ErbB2 or ErbB3 can markedly suppress the
growth of breast cancer cells (Faltus, Yuan et al. 2004; Lee-Hoeflich, Crocker et al. 2008).
As a result of these observations, inhibition of ErbB2/ErbB3 signaling has become a very
attractive goal in the clinical treatment of breast cancer. Current efforts to suppress this
signaling pathway have been mostly focused on ErbB2, targeting either the extracellular
ligand-binding and dimerization region using therapeutic antibodies or intracellular
kinase activity with small molecule inhibitors. Some of these ErbB2-targeted drugs, such
as Herceptin and Tykerb (lapatinib), are among the most famous breast cancer drugs
(Park, Neve et al. 2008) and have proven to be effective in some patients with breast
cancer characterized by ErbB2 overexpression (Nahta and Esteva 2006; Bedard, Cardoso
et al. 2009).
Despite significant advances with ErbB2-directed therapies in breast cancer,
effectiveness of these treatments is modest at best. These drugs work for only a small
subset (<25%) of patients – even within the group showing ErbB2 gene amplification and
overexpression (Chen, Xia et al. 2008), and development of resistance is a very
significant problem (Chen, Xia et al. 2008; Bedard, Cardoso et al. 2009). ErbB3 has
recently become a focus of attention, as it appears to play an important role in escape
6

from (or resistance to) therapeutic agents that target ErbB2 in cancer. Sergina et al.
showed that the BT474 and SKBR3 breast cancer cell lines become resistant to gefitinib,
an ErbB TKD inhibitor, within 24 hours of treatment, and this correlates with a recovery
in ErbB3 (but not ErbB2) phosphorylation and corresponding Akt activation (Sergina,
Rausch et al. 2007). Suppression of ErbB kinase activity with gefitinib also appeared to
induce relocalization of the ErbB3 protein from intracellular compartments to the plasma
membrane, which was proposed to facilitate its interaction with other ErbBs, contributing
to inhibitor resistance. Similarly, breast cancer cell lines that are resistant to Herceptin
(an ErbB2 antibody) can be inhibited by antibodies against ErbB3 (van der Horst, Murgia
et al. 2005).
ErbB3 also plays a similar role in drug resistance of non-small cell lung cancer
(NSCLC) associated with EGFR overexpression or mutation. In gefitinib-sensitive
NSCLC cell lines, ErbB3 is found to be associated with the PI3K p85 subunit and
mediates signaling from activated EGFR to the downstream Akt pathway via PI3K.
Alternatively, ErbB3 can contribute to the development of gefitinib resistance in NSCLC
cell lines through partnering with another receptor tyrosine kinase MET. MET
amplification causes hyper-phosphorylation of ErbB3 even in the presence of gefitinib.
Similar ErbB3-mediated EGFR activation of Akt signaling has been reported in erlotinib
sensitive pancreatic and colorectal tumor cell lines (Buck, Eyzaguirre et al. 2006).
Consistent with these observations, down-regulation of ErbB3 using RNA interference
(RNAi) can restore the sensitivity of cancer cells to gefitinib or erlotinib – with
associated reduction of activated phospho-Akt levels. Where MET is involved, small
7

molecule inhibitors of its tyrosine kinase can also restore geftinib sensitivity (Engelman,
Zejnullahu et al. 2007). By contrast with these observations, gefitinib-resistant NSCLC
cell lines show no detectable association of ErbB3 with PI3K-p85 or Akt sensitivity to
ErbB3 knockdown (Engelman, Janne et al. 2005).
Due to an increasing realization that ErbB3 is a key contributor to development of
cancers and their drug resistance, many pharmaceutical companies are actively pursuing
antibodies that specifically target ErbB3 in order to suppress its oncogenic signaling. One
ErbB3 antibody called MM-121 (Merrimack Pharmaceuticals Inc.) has been developed to
suppress ligand-induced ErbB3 phosphorylation in cancer cell lines and, when combined
with the EGFR-targeted cetuximab antibody, it suppresses cetuximab resistance in a
mouse lung cancer model driven by an EGFR T766M/L834R dual mutation (Schoeberl,
Faber et al.). Multiple phase I&II clinical trials are currently being conducted to test the
efficacy of this therapeutic agent in multiple settings. Other ErbB3-specific antibodies
undergoing clinical trials include U3-1287 generated by U3 Pharma & Amgen and MPRM-1 by MediaPharma (Sala, Traini et al.). Recently, a novel dual-specific ErbB3/EGFR
antibody, MEHD7945A, has been developed by Genentech, and has shown promising
result in studies of suppression of solid tumors (Schaefer, Haber et al.). MEHD7945A is
currently in phase II clinical trials for squamous cell carcinoma of the head and neck and
in a phase I clinical trial for epithelial tumors. Despite these developments, however,
therapeutically inactivating ErbB3 through extracellular targeting with antibodies will be
a challenging task, since the majority of ErbB3 has been reported to be located in
intracellular compartments rather than at the cell surface (Sergina, Rausch et al. 2007).
8

Whereas much effort has been put into inactivating ErbB3 with antibodies that
target its extracellular regions, the ErbB3 kinase domain has been ignored so far. The
primary reason for this is that ErbB3 has been deemed ―kinase-dead‖ due to the sequence
alterations in its TKD mentioned above (Hanks, Quinn et al. 1988; Prigent and Gullick
1994). Based on this notion, it has been assumed that all tyrosine phosphorylation in the
ErbB2/ErbB3 heterodimer arises from ErbB2‘s kinase activity (Citri, Skaria et al. 2003;
Holbro and Hynes 2004). This creates a problem, however, because studies of ErbB
signaling mechanisms argue that autophosphorylation of ErbB receptors within ligandinduced dimers occurs in trans, with each ErbB kinase mediating tyrosine
phosphorylation of its dimerization partner (Honegger, Kris et al. 1989; Honegger,
Schmidt et al. 1990; Lammers, Vanobberghen et al. 1990). According to this model, it is
unclear how ErbB2 could become phosphorylated in an ErbB2/ErbB3 heterodimer unless
ErbB3 carries an active kinase. Consistent with this possibility, recent studies of some
other presumed ―pseudokinases‖, such as Wnk, CASK, VASP and KSR, have revealed
that they do retain kinase activity in spite of previous sequence-based assumptions that
they are ―kinase dead‖ (Min, Lee et al. 2004; Mukherjee, Sharma et al. 2008; Villa,
Capasso et al. 2009; Brennan, Dar et al.). Similar to ErbB3, these presumed
pseudokinases all contain sequence alterations at key conserved residues in their kinase
domain, but can nonetheless catalyze the phosphoryl transfer reaction through noncanonical mechanisms. It is therefore important to take a closer look at ErbB3‘s TKD,
and to test the hypothesis that ErbB3, like other active pseudokinases, does in fact
function as an active kinase to promote ErbB signaling. If this is the case, targeting the
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ErbB3 kinase domain may be a promising and important novel therapeutic strategy in
cancer treatment.
1.1.4

Structure and Biochemistry of Tyrosine Kinase Domains

To understand the special properties of ErbB3 kinase domain, we first need to discuss the
general features of tyrosine kinase domains. The overall structure of protein kinase
domains (both tyrosine kinases and Ser/Thr kinases) is highly conserved, comprising an
N-lobe and a C-lobe (Figure 1.2A). The N-lobe contains five antiparallel β-strands and
one α-helix (called αC), whereas the C-lobe is mostly α-helical. Binding sites for MgATP and phosphorylation substrate are located between these two lobes, next to the
activation loop that links these two lobes.
Several key regions and conserved residues around the active site have been
implicated in kinase regulation and in catalysis itself (Figure 1.2B). For many protein
kinases, trans-phosphorylation of key Ser/Thr/Tyr residue(s) in the activation loop
prevents it from forming auto-inhibitory interactions and effectively stabilizes the active
conformation of the kinase domain (Hubbard, Mohammadi et al. 1998). However, it
should be noted that this is not the case for EGFR (discussed in the following paragraphs).
Coupled with release of the activation loop from its auto-inhibitory position is a repositioning of the αC helix in the N-lobe, which utilizes a Glu side-chain (replaced by
His740 in ErbB3) to form an ion pair with the ε-amino group of a highly conserved Lys
from the VAIK motif in β3 strand. The latter also interacts directly with the ATP α- & βphosphates and promotes ATP binding in the active conformation (Huse and Kuriyan
10

2002). A Lys to Met mutation at this position impairs the kinase activity of most kinases
(Qian, Levea et al. 1994). A conserved Asp residue (replaced by Asn815 in ErbB3) from
an also-conserved HRD motif is located between the ATP γ-PO4 and the side chain of the
substrate tyrosine, marked Asp1 in Figure 1.2B (Williams, Wang et al. 2000). Another
key Asp from the conserved DFG motif (Asp2 in Figure 1.2B) is responsible for
coordinating Mg2+ ions with ATP phosphate groups. Upon binding to the catalytic cleft
of the TKD, the substrate peptide remains largely exposed to solvent. Consequently,
unlike most enzymes, tyrosine kinases usually have low substrate specificity in vitro (Fan,
Wong et al. 2005).
The catalytic process of tyrosine kinases is still not fully understood. Since the
major sequence alteration in the ErbB3 TKD is the substitution of the Asp in HRD motif
(Asp1 in Figure 1.2B) with Asn815, the catalytic role of this key Asp is discussed here.
This Asp was initially thought to function as a general base, deprotonating the tyrosyl
side chain of the substrate so that the latter becomes a good nucleophile to attack the γphosphate group of ATP in an associative manner (Stamos, Sliwkowski et al. 2002). In
the associative mechanism, bond formation between the attacking nucleophile and the γPO4 precedes the leaving of the ADP moiety (Cleland and Hengge 1995). Current
enzymatic studies of tyrosine kinases, however, instead favor a dissociative mechanism,
in which the reaction order at this stage is reversed and the ADP moiety leaves first. In
this mechanism, the nucleophilicity of the phosphate acceptor is less important (Cleland
and Hengge 1995; Cole, Courtney et al. 2003; Shen, Hines et al. 2005). In fact, a neutral
Tyr sidechain seemed to be a better substrate than the negatively charged tyrosinate in
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studies of the Csk tyrosine kinase (Kim and Cole 1997; Kim and Cole 1998) and the role
of Asp1 was hypothesized to be stabilization of a preferred rotamer of the tyrosine
hydroxyl to facilitate the reaction process (Adams 2001).
Catalytic activity of tyrosine kinases is tightly regulated in cells, and EGFR has
been used as a model system for studying the activation of ErbB family kinases. Unlike
most tyrosine kinases, although EGFR TKD contains a tyrosine in the activation loop,
phosphorylation of this tyrosine is not required for EGFR kinase activation (Tice,
Biscardi et al. 1999). Zhang et al. (Zhang, Gureasko et al. 2006) have shown that the
EGFR kinase domain is activated through the formation of an asymmetric homodimer
(Figure 1.2C) – in which the C-lobe of the activating kinase domain (yellow in Figure
1.2C) interacts with the N-lobe αC region of the activated kinase (blue in Figure 1.2C),
inducing allosteric alterations and stabilizing the latter in the active conformation.
Mutations in the crystallographically observed interface between the activating kinase
and the activated kinase disrupt dimer formation and EGFR activation. In addition, the
juxtamembrane region of EGFR is now known to contribute to stabilization of the
asymmetric dimer shown in Figure 1.2C by wrapping around the C-lobe of the activating
kinase domain as a so-called juxtamembrane ‗latch‘ (Jura, Endres et al. 2009; Red
Brewer, Choi et al. 2009). A similar allosteric activation mode through asymmetric
dimerization has also been described for ErbB4 (Qiu, Tarrant et al. 2008).
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Figure 1.2: Structural features of tyrosine kinase domain. (A) Overall structure of tyrosine kinase domain in
the active conformation (PDB 1IR3). Dark red: ATP; Orange: activation loop; Blue: peptide substrate
(tyrosine sidechain is shown); Green: magnesium ion. (B) Close view of TKD active site. (C) Asymmetric
dimer of EGFR TKD (adapted from (Zhang, Gureasko et al. 2006)). Yellow: activating kinase; Light blue:
activated kinase.

1.1.5

ErbB3, a Heretical Kinase with Changes at Conserved Catalytic Residues in

TKD
As mentioned in the previous section, the ErbB3 kinase domain harbors amino acid
substitutions at two key conserved sites. First, an Asn (N815) replaces the conserved
catalytic Asp in the HRD motif (Asp1 in Figure 1.2B) that lies near the γ-PO4 of ATP
and the side chain hydroxyl of the substrate tyrosine. Other than being important for full
catalytic activity in other kinases, the exact function of this aspartate is the subject of
much debate. Site-directed mutagenesis of this aspartate in protein kinase A (Gibbs and
Zoller 1991) and the Csk tyrosine kinase (Cole, Grace et al. 1995) substantially reduces
(but does not abolish) kinase activity. Moreover, a D813A EGFR mutant is still capable
of mediating EGF-induced DNA synthesis (suggesting some residual kinase activity),
whereas a K721R (kinase-dead) EGFR mutant cannot (Coker, Staros et al. 1994). These
findings argue that replacement of this Asp with Asn815 in ErbB3 does not necessarily
imply an absence of kinase activity.
The second amino acid substitution in ErbB3 TKD occurs at the conserved Glu
site in the C helix (Glu-C in Figure 1.2B), which in other kinases forms a salt bridge
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with lysine in the VAIK motif and contributes to stabilization of the ATP binding site in
the active conformation. This Glu is replaced in ErbB3 by a histidine (H740). However,
the effect of mutating this residue is not well understood. It should also be noted that the
sequence of ErbB3 in the αC helix region is very different from that in other kinases, so
that an alternative structural solution might exist to stabilize the active conformation.
Apart from these two mutations, other conserved residues near the ATP binding pocket
thought to be crucial for kinase activity are all ―intact‖ in ErbB3.
Following the initial cloning of ErbB3, and realization that its kinase domain
harbors these unusual differences from ‗canonical‘ protein kinases, several early
biochemical studies investigated ErbB3 kinase activity and concluded qualitatively that it
is kinase-inactive (Guy, Platko et al. 1994; Sierke, Cheng et al. 1997). Insect cellexpressed recombinant ErbB3 intracellular domain was reported neither to bind ATP nor
to become autophosphorylated in vitro (Sierke, Cheng et al. 1997). On the other hand,
full-length ErbB3 protein expressed in insect cells could be affinity labeled with an ATP
analogue through crosslinking (Guy, Platko et al. 1994), but was autophosphorylated
only to a very small extent that was not increased by addition of ligand neuregulin – and
was therefore ascribed to ‗background‘ trans-phosphorylation by endogenous insect cell
kinases (Guy, Platko et al. 1994). Based on these findings, the prevailing view in the
literature is that the ErbB3 kinase domain is an inactive ‗pseudokinase‘ (Citri, Skaria et
al. 2003; Boudeau, Miranda-Saavedra et al. 2006). These initial studies should be
interpreted with caution, however. The in vitro studies of the ErbB3 intracellular domain
only investigated diluted protein in solution (Sierke, Cheng et al. 1997) – whereas the
15

EGFR precedent argues that dimerization is likely to be required for kinase activation.
Moreover – although the authors did not realize this at the time – neuregulin binding
does not induce ErbB3 homodimerization (Berger, Mendrola et al. 2004), so the cellular
studies of full-length ErbB3 never actually subjected the protein to a treatment that may
activate its kinase activity. Therefore, these prior studies failed to investigate ErbB3
kinase activity under conditions where activity (if present) would be manifest (i.e.
following dimerization or oligomerization). Nonetheless, all proposed signaling
mechanisms involving ErbB3 have assumed that it has no kinase activity.
1.1.6

Summary

ErbB3 is a unique member of the ErbB family RTKs. It contains an atypical kinase
domain and an extracellular domain that exclusively forms heterodimers with other
ErbBs. ErbB3 plays an important role in the development of cancers, especially when
partnered with ErbB2. In oncology, current ErbB3 targeting therapeutic strategies only
focus on developing specific antibodies for ErbB3 ectodomain. On the other hand, the
ErbB3 kinase domain has not been pursued therapeutically as it is unclear whether
ErbB3 is a functional kinase.
Other than the observation of amino acid alterations in ErbB3 TKD, few
experimental studies have attempted to address the question of whether ErbB3 is able to
function as a kinase, especially under the conditions similar to those necessary for other
ErbB kinases to become activated. An increasing number of studies have discovered that
many of the presumed-inactive pseudokinases actually retain significant activity.
16

Therefore, it is inappropriate to assume that ErbB3 is ‗kinase-dead‘ simply based on these
observations. If ErbB3 is an active kinase, targeting this activity would offer a novel and
very promising treatment for ErbB2/ErbB3 expressing breast cancers that are resistant to
Herceptin and Tykerb. My study aims to investigate, using updated knowledge of ErbB
kinases, whether ErbB3 kinase retains catalytic activity and to understand the role of
ErbB3 TKD in cell signaling.
1.2

In vitro Characterization of the Enzymatic Activity of ErbB3 TKD

1.2.1

Autophosphorylation of the Purified ErbB3 Intracellular Domain

N-terminally 6xHis-tagged ErbB3 intracellular domain (ErbB3-ICD, residues 665-1323)
and isolated tyrosine kinase domain (ErbB3-TKD, residues 665-1001) were expressed in
baculovirus-infected Sf9 cells and proteins were purified as described in Experimental
Procedures. Neither ErbB3-ICD nor ErbB3-TKD showed any autophosphorylation
activity when incubated with only Mg2+ and ATP in solution, consistent with previously
published studies (Sierke, Cheng et al. 1997). However, robust tyrosine
autophosphorylation could be seen in anti-phosphotyrosine Western blots (Figure 1.3A)
when lipid vesicles containing DOGS-NTA-Ni (1, 2-dioleoyl-sn-glycero-3-([N(5-amino1-carboxypentyl)iminodi-acetic acid] succinyl) nickel salt) were added to the reaction
system, allowing 6xHis-tagged ErbB3-ICD to be clustered onto the vesicle surfaces
(Figure 1.3A, two right-most lanes). This method was used previously to promote
assembly of 6xHis-tagged signaling molecules on membrane surfaces for several
receptors (Shrout, Montefusco et al. 2003), and was crucial for activity in earlier studies
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of EGFR kinase activation by Kuriyan and colleagues (Zhang, Gureasko et al. 2006).
Autophosphorylation is also dependent on the addition of Mn2+ or Mg2+ ions (Figure
1.3B), with Mn2+ slightly preferred. Consistent with the fact that ErbB3 phosphorylation
sites are concentrated in the C-terminal tail, removing this region to give ErbB3-TKD is
accompanied by a loss of detectable autophosphorylation.
To confirm that the autophosphorylation shown in Figure 1.3A arises from
ErbB3-ICD protein, and not from other contaminating kinases, we assessed the ability of
a K723M-mutated form of the protein to autophosphorylate under the same conditions.
This conserved Lys is important for ATP-binding to the tyrosine kinase domain, and
mutation of the analogous residue is well known to abolish the activity of many kinases,
including EGFR (Honegger, Dull et al. 1987; Zhang, Gureasko et al. 2006). As shown in
the second lane of Figure 1.3C, the K723M mutation greatly diminishes the degree of
ErbB3-ICD autophosphorylation. However, the K723M-mutated ErbB3-ICD protein is
trans-phosphorylated robustly on its C-terminal tail when the 6xHis-tagged isolated
ErbB3-TKD is added, as shown in lane 3 of Figure 1.3C. On the other hand, the ability to
trans-phosphorylate ErbB3-ICD is substantially diminished when the added ErbB3-TKD
also harbors a K723M mutation (Lane 4 in Figure 1.3C and lane 5 of Figure 1.3D left).
Similarly, a K723R mutation also disrupts the kinase activity of ErbB3-TKD (lane 4 of
Figure 1.3D right). The ErbB3 TKD contains a tyrosine (Y849) in its activation loop. To
test the hypothesis that phosphorylation of this tyrosine activate kinase activity, Y849
was mutated to Glu to mimic the negatively charged phosphotyrosine. This mutation
impairs the ability of ErbB3-TKD to trans-phosphorylate the ICD‘s C-terminal tail (Lane
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6 in Figure 1.3D left), arguing against this hypothesis, but nonetheless suggesting some
role for this tyrosine in regulation of ErbB3‘s kinase activity. In addition, the Ala
substitution of V836 at the beginning of the activation loop also showed diminished
kinase activity (Lane 5 in Figure 1.3D right) and its implication will be discussed in
sections 1.3 and 1.4. We also asked whether reintroduction of the Asp at the position
occupied by the proposed catalytic base in other kinases (in the N815D mutant) can
increase the trans-phosphorylation activity of ErbB3-TKD. As shown in Lane 7 of Figure
1.3D (left), the N815D mutation did not have a significant activating effect, consistent
with a previous report (Prigent and Gullick 1994).
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Figure 1.3: Autophosphorylation of the ErbB3 Intracellular Domain in vitro. (A) ErbB3-ICD
autophosphorylation monitored by immunoblotting with anti-phosphotyrosine antibodies. ErbB3-ICD at 3
M was incubated at 25˚C in 100 mM MOPS, pH 7 containing 2 mM MnCl2, 5 mM MgCl2, 200 mM NaCl,
5 % glycerol, and 0.1 mM DTT. Lane 1 contained molecular weight markers. For lane 2, 125 M
phospholipid (in vesicles) containing 10% (mole/mole) DOGS-NTA-Ni was added to 3 M ErbB3-ICD.
Lanes 3 and 4 represent duplicate samples in which 1 mM ATP and control vesicles (lacking DOGS-NTANi) were added to 3 M ErbB3-ICD. In lanes 5 and 6, 1 mM ATP plus DOGS-NTA-Ni vesicles were
added, and significant autophosphorylation was seen. Reactions were stopped after 30 mins by adding
50 mM EDTA and SDS-PAGE gel-loading buffer. Samples were subjected to SDS-PAGE and
immunoblotting with anti-phosphotyrosine antibodies (upper panel) and an anti-pentahistidine antibody
(lower panel) for loading control. (B) Dependence on divalent cation concentration of ErbB3-ICD
autophosphorylation. Purified ErbB3-ICD (3 M) was incubated for 30 minutes in 100 mM MOPS pH 7.4,
containing 1 mM ATP, 125 M phospholipid (in vesicles) with 10 % (mole/mole) DOGS-NTA-Ni, and the
noted concentrations of MnCl2 or MgCl2. (C) For lane 1, 3 M ErbB3-ICD was allowed to
autophosphorylate as in lanes 5 and 6 of (A). K723M-mutated ErbB3-ICD was treated identically for lane 2,
and little autophosphorylation was observed. Autophosphorylation of K723M-mutated ErbB3-ICD was
recovered when the wild-type isolated ErbB3-TKD665-1001 was added at 6 M (lane 3), and to a significantly
lesser extent when K723M-mutated ErbB3-TKD665-1001 was added (lane 4). Thus, the isolated ErbB3-TKD
can phosphorylate ErbB3-ICD in trans. (D) The ability of wild-type and mutated ErbB3-TKD665-1001 to
trans-phosphorylate ErbB3-ICD was compared as described in the text.
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Although these results demonstrate that ErbB3 is capable of catalyzing
phosphoryl-transfer, we found that its catalytic efficiency is substantially lower than seen
for EGFR activated in a similar manner. We have not been able to detect significant
phosphorylation of added poly(Glu:Tyr) substrates or of short peptides modeled on
phosphorylation sites within ErbB3 or ErbB2. Experiments in which the incorporation of
32

P into the ErbB3 intracellular domain was used to monitor rates of trans-

phosphorylation (Figure 1.4) suggested that ErbB3-TKD phosphorylates ErbB3-ICD at a
rate that is about 1000 fold slower than that seen for EGFR under similar experimental
conditions. Nonetheless, the experiments in Figure 1.3 show that ErbB3 does contain an
active kinase domain.
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Figure 1.4: Quantitation of 32P incorporation into ErbB3-ICD by the kinase domains from ErbB3 or EGFR.
A final concentration of 3 μM wild-type ErbB3-TKD or EGFR-TKD was co-incubated with 6 μM 6xHistagged ErbB3-ICD (K723M) as substrate in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% glycerol,
containing 0.1 mM DTT, 5 mM MgCl2, 2 mM MnCl2, 100 μM ATP (with 3 μCi [γ-32P]ATP) and 100 μM
lipid (vesicles containing 10% DOGS-NTA-Ni with 90% DOPC). Reaction mixtures were incubated at
room temperature for the times listed, and reactions were stopped by adding EDTA to a final concentration
of 50 mM. Samples were spotted onto phosphocellulose paper to immobilize protein. After a series of
washes, 32P incorporation was measured by scintillation counting. Mean range of variation are plotted from
at least two independent experiments. 32P incorporation catalyzed by ErbB3-TKD occurred at
approximately 209 cpm per minute (5,087 in 25 min; 10,698 in 50 min). 32P incorporation catalyzed by
EGFR-TKD was clearly saturating (or depleting substrate) by 25 min. On the basis of the 1-min time point,
we estimate a maximum incorporation rate of 198,575 cpm per minute, suggesting a rate that is ∼940-fold
higher than that for ErbB3-TKD.

1.2.2

ErbB3 TKD Fully Retains ATP Binding Ability

Having detected kinase activity with our ErbB3 proteins, we next investigated the ATPbinding properties of ErbB3-TKD, since previous analyses have yielded conflicting
results (Guy, Platko et al. 1994; Sierke, Cheng et al. 1997). We used mant [2'-(3')-O-(Nmethylanthraniloyl)]-ATP, a fluorescent analogue of ATP, for direct binding studies. As
shown in Figure 1.5A, a solution of 1 M mant-ATP (plus 5 mM MgCl2) does not have
significant fluorescence when excited at 280 nm. However, following addition of ErbB3TKD at 3 M there is a significant peak centered at 448 nm that reflects fluorescence
resonance energy transfer (FRET) from tryptophans and/or tyrosines in the protein to the
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mant-ATP. The peak at 448 nm is absent without mant-ATP, and the observed FRET
requires that ErbB3-TKD, MgCl2, and mant-ATP are all present in the sample (Figure
1.5B). Moreover, FRET is substantially diminished when 20 M ATP is added (a 20-fold
excess over mant-ATP), which should saturate the nucleotide-binding site in the kinase.
These results argue that the ErbB3 kinase domain does indeed bind ATP.
To estimate the affinity of this binding, we monitored FRET from the kinase to
mant-ATP upon titration of ErbB3-TKD into a solution containing 0.6 M mant-ATP
plus 5 mM MgCl2. A simple hyperbolic binding curve was observed, as shown in Figure
1.5C, which suggested a KD value of 1.1 M for Mg2+/mant-ATP binding to ErbB3-TKD.
This is lower than KD values measured for Mg2+/ATP binding to EGFR (Cheng and
Koland 1998) or protein kinase A (Iyer, Garrod et al. 2005). It is also smaller than
apparent KM values for (Mg2+ or Mn2+) ATP measured for EGFR (Qiu, Tarrant et al.
2009), ErbB2 or ErbB4 (Qiu, Tarrant et al. 2008). Consistent with the significant
reduction in autophosphorylation activity seen for the K723M mutant in Figure 1.3,
substitution of this lysine with methionine also greatly diminishes mant-ATP binding to
ErbB3-TKD (Figure 1.5C). We have also performed some preliminary mant-ATP
binding experiments with the K723R and V836A mutants of ErbB3 TKD, and the results
suggested that the K723R mutant retains ATP binding affinity, while the V836A
mutation disrupts ATP binding (Figure 1.5D).
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Figure 1.5: Mant-ATP Binding to ErbB3-TKD648-1001. (A) Fluorescence emission spectra (with excitation
at 280 nm) are shown for 1 M mant-ATP (plus 5 mM MgCl2) in the absence of ErbB3-TKD (black) and
with 3 M added ErbB3-TKD648-1001, illustrating FRET between the protein and bound mant-ATP. (B)
Fluorescence emission of 1 μM mant-ATP at 450 nm under different conditions (with excitation at 280 nm).
No significant protein-to-mant FRET is seen for 1 M mant-ATP alone, or any pairwise combination of
1 M mant-ATP, 5 mM MgCl2, and 3 M ErbB3-TKD648-1001. However, when all three are added together,
significant fluorescence emission is seen at 450 nm, signifying mant-ATP binding. The FRET signal is
greatly reduced by adding 20 M ATP to saturate the nucleotide-binding site in the kinase (far-right
column), indicating that FRET reflects specific binding to the ATP-binding site. (C) Titration of ErbB3TKD648-1001 into a solution of 0.6 M mant-ATP containing 5 mM MgCl2 causes an increase in fluorescence
emission from mant-ATP at 450 nm (via FRET from the protein to which it is bound). The resulting
hyperbolic binding curves were fit to a simple binding equation, yielding a best-fit KD value of 1.1 M for
wild-type ErbB3-TKD. A K723M mutation variant greatly diminished (but did not abolish) mant-ATP
binding. (D) Mutating V836 in ErbB3-TKD665–1001 disrupts mant-ATP binding. Samples containing buffer
alone or mutated ErbB3-TKD at 10 μM were incubated alone (fourth set of bars), with 5 μM mant-ATP
(third set of bars), with 5 μM mant-ATP plus 10 mM MgCl2 (first and second sets of bars), or with 5 μM
mant-ATP, 10 mM MgCl2 plus 500 μM ATP (fifth set of bars). Assays were performed in 20 mM Tris pH
8.0, 200 mM NaCl, 5% glycerol. Fluorescence measurements were taken in triplicate using a Tecan
SAFIRE II plate reader, with excitation wavelength of 340 nm and emission wavelength of 450 nm (10-nm
bandwidth for both). The K723R mutant binds mant-ATP with an affinity similar to that seen for wild-type
protein and shows a substantial increase in fluorescence emission from mant-ATP that can be competed
away by addition of excess ATP. By contrast, the V836A mutant displayed little evidence of binding,
consistent with the loss of the ability of V836A-mutated ErbB3-ICD to autophosphorylate as assessed in
immunoblotting assays. Note that the first and second sets of bars are experimental repeats.
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1.2.3

Inhibitor Profiling of ErbB3 Kinase

We next investigated whether currently available kinase inhibitors (especially those
targeting ErbB kinases) can inhibit the kinase activity of ErbB3. This study serves two
purposes:
1) Since these inhibitors all target the ATP binding pocket of kinases, an inhibitor
sensitivity ‗profile‘ will provide one view of the similarity between the ATP
binding pocket of the ErbB3 TKD and that of other kinases (such as EGFR) using
these inhibitors as probes.
2) The screen could potentially identify inhibitor(s) that can preferentially inhibit
ErbB3 kinase but not other ErbB kinases. Such inhibitor could be applied in
cellular studies to examine the role of ErbB3 kinase.
We first examined whether the current FDA-approved EGFR-specific inhibitors
(gefitinib, erlotinib and lapatinib) can effectively inhibit ErbB3 kinase. Figure 1.6A
shows that, at low micromolar concentration, none of the three inhibitors blocks the
kinase activity of ErbB3, whereas all of them completely inhibit EGFR kinase. This
result is not surprising since (1) these three inhibitors are optimized for EGFR and (2) the
ErbB3 kinase is more homologous to ErbB4 kinase, which is also a much weaker binder
of these inhibitors (Wood, Truesdale et al. 2004).
Next, using small inhibitor libraries containing commercially available ATPcompetitive kinase inhibitors, we examined the inhibition profile of ErbB3 kinase, to
compare it with that of EGFR kinase. Since no available inhibitor has been optimized for
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ErbB3 kinase, these experiments were performed at a higher concentration of inhibitor
(50 µM) and lower concentration of ATP (100 µM) in order to identify inhibitor
candidates that are likely to have relatively weak binding of ErbB3 kinase. The results
showed that, although the EGFR and ErbB3 kinases share fairly similar inhibition
profiles, most inhibitors that did block their activities appear to have less potency towards
ErbB3 than EGFR, represented by a smaller degree of ErbB3 inhibition in this qualitative
assay. In addition, some of the EGFR kinase inhibitors failed to block ErbB3 activity at
all. The work of our collaborators in the laboratory of Kevan Shokat at U.C.S.F. has
shown similar results. Therefore, we conclude from this study that, although the overall
ATP binding site of ErbB3 TKD is structurally similar to that of EGFR kinase, it is
targeted less effectively by current kinase inhibitors. One reason for this may be the
relatively stronger ATP binding of ErbB3 TKD compared to other kinases as determined
in our mant-ATP assay. Another reason could be that the structural configurations of
ErbB3 kinase (and its most populated states in the conformational ensemble) are weaker
binders for these inhibitors.
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Figure 1.6: Inhibitor Profiling of ErbB3 Kinase. (A) Western blot analysis to assess the effect of EGFR or
EGFR/ErbB2 inhibitors on ErbB3-TKD activity (left) and EGFR-TKD activity (right). ErbB3-ICD (0.3 μM)
was mixed with 0.3 μM ErbB3-TKD (left) or 0.3 μM EGFR-TKD (right) in 1 mM ATP (except in the first
lane), 5 mM MgCl2, 2 mM MnCl2, 10 μM lipid (10%NTA-NiDOGS + 90%DOPC in vesicles), 20 mM
Tris-HCl pH8.0, 200 mM NaCl, 5% glycerol and 0.1 mM DTT for 1 hr (left) or 1min (right) at 25 °C.
Phosphorylation was monitored by Western blotting with pY20 antiphosphotyrosine (Upper) and anti-His5
antibody for normalization (Lower). To assess inhibitor specificity, experiments were performed in the
presence of 4 μM lapatinib (L), 4 μM gefitinib (G), 4 μM erlotinib (E), or without inhibitor (DMSO only:
―-‖). All three inhibitors blocked EGFR activity, but left trans-phosphorylation by ErbB3-TKD unaffected.
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(B) Western blot analysis to assess the effect of a commercially available kinase inhibitor library (EMD#1)
on ErbB3 kinase activity (left) and EGFR kinase activity (right). 1 μM ErbB3-ICD or 0.1 μM EGFR-ICD is
incubated with 50 μM inhibitor and 100 μM ATP in kinase assay buffer (same as in A) for 1 hour (for
ErbB3) or 5 minutes (for EGFR) at 25 °C. Reactions were quenched with EDTA (100 mM final
concentration) and 2 μl of each sample was spotted onto nitrocellulose paper. After drying, phosphorylation
was monitored by Western blotting with pY20 anti-pTyr antibody and corresponding anti-mouse HRP
secondary antibody. Samples in the first column of each blot (8 samples on the left) represent kinase
reaction without inhibitor (DMSO only). Kinase inhibitors in the EMD#1 library are listed in Appendix 1.

1.3

Structural Characterization of ErbB3 Kinase Domain by X-ray

Crystallography
To gain insight into how the ErbB3 tyrosine kinase domain retains activity despite
substitutions at key residues, we determined its crystal structure. Crystals of ErbB3-TKD
grew only in the presence of 5 mM MgCl2 and the non-hydrolyzable ATP analogue
adenylyl-imidodiphosphate (AMP-PNP), and diffracted X-rays to 2.8 Å resolution (Table
1.1). The structure was solved by molecular replacement using an inactive EGFR TKD
structure as search model. The asymmetric unit contains two ErbB3-TKD molecules,
which are almost identical to one another and pack in the crystal lattice in an N-lobe to
N-lobe, C-lobe to C-lobe manner (Figure 1.7).
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Table 1.1: ErbB3 TKD crystallographic statistics (molecular replacement).
ErbB3 TKD
Data collection

APS (GM/CA CAT)

Space group

C2

a, b, c (Å),  (˚)

193.4, 48.0, 82.2,  = 108.1˚

Resolution (Å)

50.00 - 2.80 (2.85-2.80) *

Rsym or Rmerge

0.083 (0.499)

I / σI

17.1 (2.2)

Completeness (%)

90.0 (55.3)

Redundancy

6.3 (3.4)

Refinement
Resolution (Å)

50.00 – 2.80

No. reflections

14406

Rwork / Rfree

25.2/28.5

Model
Protein amino acids

aa A680-728, 732-844, 854-959

No. atoms

aa B680-711, 713-729, 732-845, 854-959
4316

Protein

4245

Ligand/ion

64

Water

7

R.m.s. deviations
Bond lengths (Å)

0.006

Bond angles (˚)

1.099

*Values in parentheses are for highest-resolution shell.
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Figure 1.7: Cartoon representation of the crystal packing of ErbB3-TKD. The green structure is molecule A
in the asymmetric unit, and the red structure is molecule B. These associate in the crystals through N-lobe
mediated interactions. In addition, interaction partners in the crystal are shown for molecule B (red) that
associate through alternative N-lobe mediated (dark blue) and C-lobe mediated (cyan) contacts. The
packing of ErbB3-TKD molecules in our crystals appear to be the same as those described and discussed in
detail by Jura et al. (Jura, Shan et al. 2009).
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As shown in Figure 1.8A, the overall structure of ErbB3-TKD closely resembles
that of the inactive conformation of the EGFR kinase (Zhang, Gureasko et al. 2006), and
in turn that of the inactive ErbB4 and Src kinase domains (Zhang, Gureasko et al. 2006;
Qiu, Tarrant et al. 2008). Although reduced in length as described below, the C helix of
ErbB3-TKD is displaced away from the active site, in the ‗out‘ position typically seen in
structures of inactive kinases (Huse and Kuriyan 2002). The activation loop of ErbB3TKD also retains the characteristic short -helix that abuts the C helix in inactive EGFR
and ErbB4 (green in Figure 1.8A), and is the site of key mutations that activate EGFR in
non-small cell lung cancer (NSCLC) (Sharma, Bell et al. 2007). One particularly notable
difference between ErbB3-TKD and the other ErbB kinases is the length of the C helix,
the amino-terminal half of which (~1.5 turns in EGFR) is unraveled in ErbB3-TKD. This
region forms a well-defined loop (residues 732-739) in ErbB3-TKD that appears to be
anchored by backbone-mediated interactions with the 4/5 loop and the projection of
the F734 side-chain into a hydrophobic pocket formed largely by side-chains from 3
(I725), 5 (L764), C (M741), and the activation loop (L839 and L840) (Figure 1.8B).
Consistent with our mant-ATP binding studies shown in Figure 1.5, we could see
clear electron density for both AMP-PNP and Mg2+ in the ErbB3-TKD structure (Figure
1.8C). The bound Mg2+ ion is coordinated by the side-chains of N820 and D833 (from
the DFG motif), plus the - and -phosphates of AMP-PNP. The -amino group of the
highly conserved K723 residue (in strand 3) interacts with both the -phosphate of
AMP-PNP and the D833 side-chain, thus playing a key role in nucleotide binding as seen
for inactive EGFR, and indicated by the substantially reduced kinase activity (Figure 1.3)
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and mant-ATP binding (Figure 1.5) in the K723M variant of the ErbB3 intracellular
domain or TKD.
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Figure 1.8: Crystal structure of ErbB3-TKD. (A) Cartoon representations are shown for ErbB3-TKD665-1001
(left: red) EGFR-TKD in its inactive configuration (Zhang, Gureasko et al. 2006) from PDB code 2GS7
(middle: cyan), and EGFR-TKD in its active configuration with a bound bisubstrate analogue of ATP and
peptide (Zhang, Gureasko et al. 2006) from PDB code 2GS6 (right: grey). Bound AMP-PNP and Mg2+ ions
are shown in spheres and marked, with only the nucleotide portion of the bisubstrate analogue shown for
active EGFR. The C helix is colored blue in each structure, and is denoted as being in the ‗out‘ position in
ErbB3 and inactive EGFR, and the ‗in‘ position in active EGFR. The short -helix in the activation loop of
ErbB3 and inactive EGFR is colored green. H740 in the C helix of ErbB3 replaces a conserved glutamate
(E738 in EGFR), and is shown in stick representation. N815 (which replaces the conserved catalytic base
D813) is also marked and shown in stick representation. -strands in the N-lobe are also labeled. (B) Closeup view of the unraveling of αC in ErbB3 TKD structure. The protein sequence (residues 732-739)
equivalent to the amino-terminal half of the EGFR αC forms a well-defined loop in ErbB3-TKD that
appears to be anchored by backbone-mediated interactions with the β4/β5 loop and the projection of the
F734 side-chain into a hydrophobic pocket formed largely by side-chains from β3 (I725), β5 (L764), αC
(M741), and the activation loop (L839 and L840). (C) Close-up view of Mg2+-AMP-PNP in the ErbB3TKD665-1001 active site, with electron density shown as a 2Fo-Fc map calculated at 1.8 with phases from a
model into which nucleotide had not been placed. Coordination of the bound Mg 2+ ion by the side-chains of
N820 and D833 (from the DFG motif), plus the - and -phosphates of AMP-PNP is depicted. The
position of N815 (close to the -phosphate) is also shown. The side-chain of K723 (in strand 3), which
interacts with the -phosphate of AMP-PNP and the D833 side-chain is occluded by the Mg2+ ion in this
view, and cannot be seen. (D) Close-up view of the short -helix seen in the activation loop of ErbB3TKD (red) and inactive EGFR-TKD (cyan), with the two kinase superimposed. Mutations at L834 or L837
in EGFR activate the receptor in NSCLC. The side-chains of these residues overlay very well with V836
and L839 in the inactive-like ErbB3-TKD structure, and interact with the hydrophobic pocket that
contributes to stabilization of the C helix in the ‗out‘ position.
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The activation loop configuration seen in ErbB3-TKD closely resembles that of
the inactive EGFR and ErbB4 kinase domains (Zhang, Gureasko et al. 2006; Qiu, Tarrant
et al. 2008), and is quite distinct from that seen for active kinases (Huse and Kuriyan
2002). The short -helix in the activation loops of EGFR and ErbB4 contains several
aliphatic side-chains (L834, L837 and L838 in EGFR) that participate in interactions with
a hydrophobic pocket formed by side-chains from the -sheet in the N-lobe and the C
helix. Mutations at L834 and L837 (L834R and L837Q) are known to activate EGFR in
some NSCLC cases (Sharma, Bell et al. 2007) by disrupting these interactions, and
appear to be oncogenic driver mutations in this cancer. ErbB4 can be activated similarly
(Qiu, Tarrant et al. 2008). Moreover, mutating residues that contribute to the hydrophobic
pocket into which these aliphatic side-chains project can activate EGFR in vitro (Choi,
Mendrola et al. 2007). In ErbB3, a conserved VLL motif (V836, L839, L840) in the short
activation loop helix makes a very similar set of interactions, apparently stabilizing the
‗inactive-like‘ position of the C helix. As shown in Figure 1.8D, residues V836 and
L839 in ErbB3 overlay almost exactly with L834 and L837 in EGFR (key sites of
activating NSCLC mutations). To investigate whether similar mutations in ErbB3 can
potentially disrupting this inactive-like conformation – we made V836R and L839Q
mutations in ErbB3 (parallel to the NSCLS mutations in EGFR), and their effects on
cellular signaling will be examined in the next section. Unfortunately, recombinant
ErbB3 TKD protein containing either of the mutations does not remain monomeric in
solution but form aggregates during purification, therefore its effect on kinase activity
cannot be measured directly by in vitro kinase assay. However, properties of a similar
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V836A mutant of ErbB3 TKD suggest that mutating this hydrophobic VLL motif may
likely disrupt this conformation, as it displays compromised ATP binding ability (Figure
1.5D) and kinase activity (Figure 1.3D).
In addition to replacement of the proposed catalytic base with an asparagine in
ErbB3 (N815), one of the notable sequence alterations that led to the assignment of
ErbB3 as a pseudokinase is replacement of the conserved glutamate in the C helix with
a histidine (H740). Interestingly, this histidine forms a predicted hydrogen bond with the
carbonyl oxygen of G835 in the ErbB3 DFG motif. Recent indications of the importance
of the conformational dynamics of the DFG motif (Jura, Shan et al. 2009) suggest that
this interaction could be relevant for controlling ErbB3 kinase activity. In the inactive
EGFR TKD, E738 does not make an equivalent predicted hydrogen bond, but may
interact with the side-chain of K836 that follows the DFG motif in EGFR.
The crystal structure of ErbB3 has revealed important structural features of ErbB3
TKD and its binding mode to ATP. However, it is unclear whether the catalytic activity
observed in our in vitro assays is mediated by this conformation, since it closely
resembles the inactive conformation of EGFR kinase. On the other hand, since ErbB3‘s
enzymatic activity is much lower than EGFR, it is possible that this limited catalysis of
the phosphoryl transfer reaction could be mediated through this unusual conformation.
Indeed, QM/MM simulations by the Radhakrishnan lab at U. of Penn. have depicted a
possible reaction pathway for ErbB3 to catalyze tyrosine phosphorylation in such a
conformation (Figure 1.9) (Shi, Telesco et al.). The estimated activation energy (Ea) for
phosphoryl transfer is 23 kcal/mol for ErbB3 kinase in this conformation, higher than the
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16 kcal/mol activation energy for EGFR kinase in the active conformation, consistent
with the fact that ErbB3 is a relatively weaker kinase. At this point, we do not have
evidence to support or disregard the possibility that alternative conformation(s) of ErbB3
TKD contribute to its catalytic activity.
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Figure 1.9: QM/MM simulations of phosphoryl transfer of ErbB3 and EGFR kinases (Shi, Telesco et al.
2010). Schematic of the phosphoryl-transfer pathway in (A) EGFR-TKD and (B) ErbB3-TKD, as captured
in QM/MM simulations. Mg2+ ions are marked, as are the catalytic aspartates (D831 in EGFR, D833 in
ErbB3), the proposed catalytic base in EGFR (D813), and its replacement in ErbB3 (N815). Two potential
pathways for proton migration (concomitant with phosphoryl transfer) are marked as described in the text:
pathway I (Red) and pathway II (Green). The distance from the substrate -OH proton to the Oδ2 oxygen of
D813 in EGFR is labeled δI, and its distance to the O1γ oxygen of ATP is δII. (C–F) Energy changes along
the reaction pathway in QM/MM simulations for the noted mechanisms involving pathway II (Green) or
pathway I (Red). States correspond to ―R‖ (reactant); ―TS‖ (transition state with trigonal-bipyramidal
geometry around Pγ); ―P‖ (product after phosphoryl transfer with proton bound to ATP O1γ); and ―P2‖
(product with proton transferred to ATP O2β) (C) Energy changes along the simulated ErbB3 reaction
pathway. Symbols bounded by black squares represent the forward scan, and those bounded by gray
squares represent the reverse scan. Only pathway II is utilized, and estimated Ea for phosphoryl transfer is
23 kcal/mol. (D) Energy changes along the EGFR reaction pathway (active configuration) utilizing
pathway II and the associative mechanism: Estimated Ea is 24 kcal/mol. (E) Phosphoryl transfer catalyzed
by EGFR via the dissociative mechanism (utilizing pathway I for proton migration—via D813) has the
lowest Ea value, at 16 kcal/mol. (F) Associative phosphoryl transfer concomitant with pathway I for EGFR
has an estimated Ea of 24 kcal/mol. See supplementary materials of (Shi, Telesco et al. 2010) for details.

1.4

Cellular Studies to Investigate the Role of ErbB3 Kinase Domain in ErbB

Signaling
It is unclear from the in vitro assays described above whether the weak catalytic activity
of ErbB3 plays a physiologically relevant role in cellular ErbB signaling. Since the kinase
activity of ErbB3 TKD is about 1000 fold weaker than that of EGFR kinase (and other
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ErbB kinases), and upon ligand binding ErbB3 forms heterodimers with other ErbB
family proteins (rather than homodimer), it seems plausible that ligand-induced ErbB
autophosphorylation in cells is carried out predominantly by the other ErbB kinase in the
heterodimer. On the other hand, even with weaker kinase activity, ErbB3 may still
function as a kinase in cells, especially during abnormal cancer development. Indeed, a
weak kinase activity may be sufficient for trans-phosphorylation of heterodimerization
partners, with the higher activity levels seen for EGFR and ErbB2 only being necessary
for the phosphorylation of downstream signaling molecules such as PLC, Shc, and other
examples.
In efforts to investigate the cellular role of ErbB3‘s kinase activity, we introduced
exogenous full length ErbB3 into BaF3 and CHO cells, which lack significant
endogenous ErbB3 expression, and investigated whether amino acid substitutions in the
ErbB3 kinase domain affect ErbB3-dependent signaling. Among the mutations that have
been introduced, K723M, K723R and V836A mutants show significantly compromised
kinase activity in in vitro kinase assays (Figure 1.3D). Whereas ATP binding to the
K723R mutant is retained (Figure 1.5D), ATP binding to the V836A and K723M variants
is greatly reduced (Figure 1.5C&D) – consistent with their loss of kinase activity. Two
other mutants (V836R and L839Q) are tested here since the equivalent mutations in
EGFR kinase disrupt the packing of the conserved hydrophobic patch in the beginning of
activation loop (in the inactive conformation) and play oncogenic roles in NSCLC cells.
I919R is located on the C-lobe of ErbB3, and would be predicted to impair the ability of
ErbB3 to function as an ―activator‖ in asymmetric ErbB TKD dimers – thus disrupting
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the ability of ErbB3 TKD to activate its dimerization partner‘s kinase domain in an ErbB
heterodimer.
1.4.1

Effect of ErbB3 mutations on Autophosphorylation of ErbB2/ErbB3

Heterodimers in BaF3 Cells
We first investigated whether ErbB3‘s kinase activity is required for ErbB
autophosphorylation in ErbB2/ErbB3 heterodimers induced by neuregulin binding. We
used BaF3 cells as a ‗null‘ background for these studies, since these murine pro-B cells
contain no detectable EGFR, ErbB2, or ErbB4 – although a low level of ErbB3
expression can be detected at the mRNA level. BaF3 cells are commonly used as a
cellular background in studies of ErbB receptor properties for these reasons (Riese, van
Raaij et al. 1995). Co-expression of full length ErbB3 protein (wildtype or mutated) and
wildtype ErbB2 protein in BaF3 cells was achieved through transfection of pIRES
plasmids that allow dual expression of both cDNAs. After selecting for stable cell lines
co-expressing the desired combination of receptor variants, cells were stimulated with the
ErbB3 ligand neuregulin1β (Nrg1β), and ligand-induced ErbB autophosphorylation was
examined by Western blotting (Figure 1.10A&B). Tyrosine phosphorylation levels of
ErbB2 and ErbB3 was detected using 3 different phosphotyrosine antibodies (ErbB2
pTyr877-specific, ErbB3 pTyr1289-specific, and pan pTyr antibodies). Although the
expression levels of ErbB2 and ErbB3 variants were clearly different in each cell line
(bottom two blots in each panel) despite significant efforts to normalize them using
FACS, the data strongly suggest that mutations in the ErbB3 kinase domain did not affect
its ability to induce neuregulin-induced ErbB2 (or ErbB3) phosphorylation, clearly
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arguing against our initial hypothesis. In fact, none of the following ErbB3 mutations
seemed to have a substantial influence on ErbB2 (or ErbB3) phosphorylation when
compared with wild-type ErbB3: K723M, K723R, T768G, V836A, V836R, L839Q,
V836R/L839Q (Figure 1.10A&B), despite that the K723M, K723R and V836A
mutations substantially impair ErbB3 kinase activity in vitro (Figure 1.3C&D)
(aggregation of purified recombinant TKD protein prevented us from drawing reliable
conclusions on this for the other mutants). Taken together, these data argue that ErbB3 is
not (at least directly) the kinase responsible for ErbB autophosphorylation in the ligandinduced ErbB2/ErbB3 heterodimers in these BaF3 cell studies. The ErbB3 I919R
mutation is distant from the ATP binding pocket and disrupts the presumed ability of the
C-lobe of ErbB3 to interact ErbB2‘s N-lobe to form asymmetric dimers as depicted in
Figure 1.2C. Therefore, I919R-mutated ErbB3 will be defective in its ability to
allosterically transactivate ErbB2 kinase in ErbB3/ErbB2 heterodimers. The lack of
ligand-induced ErbB autophosphorylation in this cell line (Figure 1.10A) suggests that
ErbB2‘s kinase activity is responsible for the autophosphorylation observed in the other
cell lines carrying ErbB3 (wildtype or mutant).
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Figure 1.10: Autophosphorylation of ErbB2 and ErbB3 in ligand-induced ErbB2/ErbB3 heterodimers in
BaF3 cells. (A-B) BaF3 cells were stably transfected with pIRES plasmids containing both wildtype ErbB2
and (wildtype or mutated) ErbB3 mutants, which allows constitutive co-expression of both full length
ErbB2 and ErbB3 in the cells. Cells were selected for high ErbB expression using FACS cell sorting. For
detection of autophosphorylation, BaF3 cells were serum starved for 6 hours, then washed and resuspended
in cold PBS at a density of 1x107 cells/ml, and stimulated with neuregulin1β (50 ng/ml) for 10 min at 4 ˚C.
Cells were then lysed in RIPA buffer, and all glycoproteins were pulled down with Concanavalin A beads
(40ul beads for 107 cells) in a final volume of 100ul, and samples were prepared for Western blotting with
indicated antibodies to assess ErbB2 and ErbB3 phosphorylation.

1.4.2 Mutations within the ErbB3 Kinase Domain Affect its Ability to Activate Akt
Signaling in CHO Cells
We next investigated the effects of ErbB3 kinase domain mutations on the ability of this
receptor to activate Akt signaling in response to neuregulin. Indeed, ErbB3 has been
shown to be mainly responsible for Akt activation in the ErbB2/ErbB3 heterodimer
(Hellyer, Kim et al. 2001). We switched to CHO cells for this part of study, since the Akt
response could not easily be observed in BaF3 cells. CHO cells are well known not to
express endogenous EGFR (Xu, Nagarajan et al. 2011). And other ErbBs are expressed at
very low levels (if at all) in CHO cells (Azios, Romero et al. 2001). Accordingly, parental
CHO cells show no Akt activation response following addition of the ErbB3 ligand
(Nrg1β) (right-most two lanes in Figure 1.11). In contrast, when transfected with
wildtype full length ErbB3, CHO cells show robust activation of the Akt pathway in
response to ligand stimulation (left-most two lanes in Figure 1.11), as detected with
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antibodies specific for phosphorylated S473 of Akt (a diagnostic of Akt activation).
Similar levels of neuregulin-dependent Akt activation were observed in CHO cells
expressing the K723M-mutated variant of ErbB3, which we showed has dramatically
reduced autophosphorylation activity (in Figure 1.3C&D), and a greatly reduced affinity
for ATP (Figure 1.5C). Similarly, T768G and V836R-mutated ErbB3 variants were able
to support neuregulin-dependent Akt activation, consistent with the results from studies
of ErbB2 trans-phosphorylation in BaF3 cells. We also included the I919R ErbB3 variant
as a control since this mutation is in the C-lobe of the ErbB3 kinase domain and is
predicted to prevent it to trans-activate the other ErbB kinase in the heterodimer as
shown in Figure 1.2C. The lack of ligand induced Akt activation in I919R mutated ErbB3
variant suggested that Akt activation in these studies does involve formation of
asymmetric TKD dimers, most likely in heterodimers of ErbB3 with low levels of
endogenous ErbB2 or ErbB4 in CHO cells. Again, overall our data suggest that
suppressing the kinase activity of ErbB3 does not significantly affect its ability to signal
(via PI3K) to Akt in CHO cells.
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Figure 1.11: ErbB3 mediates neuregulin induced Akt activation in CHO cells. CHO cells were transiently
transfected with pcDNA3.1 plasmids containing full length ErbB3 (wildtype or mutant) or parental
pcDNA3.1 plasmid as indicated. 24 hours after transfection, CHO cells were serum starved overnight, and
then stimulated with neuregulin1β (40ng/ml) (or PBS as negative control) for 30 min. Then cells were lysed
in RIPA buffer and subjected to Western blotting with the indicated antibodies. For the total Akt blot, the
pAkt(S473) blot was incubated with stripping buffer after exposure to remove antibodies and was then reprobed with Akt antibodies.

Surprisingly, disrupting the hydrophobic patch that links the small -helix in the
ErbB3 activation loop with the C helix does appear to compromise ErbB3‘s ability to
activate Akt to some extent, as shown for ErbB3 harboring both the V836R and L839Q
mutations (Figure 1.12 A&B). These mutations are interesting because they correspond
structurally to the L834R and L837Q mutations in EGFR that activate EGFR‘s kinase
and are now well known to be oncogenic driver mutations in non-small cell lung cancer
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(Sharma, Bell et al. 2007). Here, in ErbB3, the equivalent mutations appear to have a
negative (rather than activating) influence on activation of Akt signaling. As shown in
Figure 1.12, the normalized level of neuregulin-dependent Akt activation was reduced by
~30% in cells expressing V836R/L839Q doubly-mutated ErbB3 compared with cells
expressing wildtype or singly mutated ErbB3 in an average over four experiments. To
further assess this effect, we performed equivalent experiments using chimeric proteins in
which the EGFR extracellular region is fused to the (wildtype or mutated) ErbB3
intracellular region – again in CHO cells (which lack EGFR). As with the ErbB3
experiments, the EGFR/ErbB3 chimera was transiently transfected into CHO cells and its
effect on ligand-induced (in this case by EGF) Akt activation was analyzed. The basic
observation was reproduced in this context (Figure 1.13): whereas single V836R or
L839Q mutations did not significantly affect the ability of the EGFR/ErbB3 chimera to
activate Akt signaling, the combined V836R/ L839Q mutations caused a significant
decrease of Akt activation upon ligand stimulation – to approximately 40% of levels
induced by wildtype ErbB3.
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Figure 1.12: V836R and L839Q double mutation in ErbB3-TKD impairs its ability to activate Akt pathway
in CHO cell. (A) Western blots of neuregulin induced Akt activation in CHO cells transfected with full
length ErbB3 (wildtype or mutant). Transfected CHO cells were serum-starved overnight, and neuregulin
1β (50 ng/ml final concentration) was added for 20 minutes. Cells were then lysed in RIPA buffer and
subjected to Western blotting with the indicated antibodies. For each Akt blot, the corresponding
pAkt(S473) blot was incubated with stripping buffer after exposure to remove antibodies and was then reprobed with anti-Akt antibodies. Blots are representative of 4 independent experiments. (B) Quantitative
analysis of Akt activation level (blue) and ErbB3 expression level (grey), calculated from all 4 independent
experiments. Band intensities (ErbB3, pAkt, Akt) were determined from Western blots using ImageJ
software. In each independent experiment, normalized Akt activation levels were calculated as the ratio of
the pAkt(S473) and Akt band intensities. ErbB3 expression levels were also normalized by total
(endogenous) Akt levels. Values from all 4 experiments were combined to calculate the final means and
standard deviations. Error bars represent one standard deviation. Significance is shown as the difference of
ligand induced Akt activation levels between CHO cells transfected with wildtype or V836R&L839Q
double mutated ErbB3 (p < 0.05).
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Figure 1.13: V836R and L839Q double mutation impairs the ability of an EGFR/ErbB3 chimeric protein to
activate the Akt pathway in CHO cells. (A) Western blots of EGF-induced Akt activation in CHO cells
transfected with an EGFR/ErbB3 chimera (wildtype or mutated). Transfected CHO cells were serumstarved overnight, and EGF (100 ng/ml final concentration) was added for 20 minutes on ice. Cells were
then lysed in RIPA buffer and subjected to Western blotting with the indicated antibodies. For each Akt
blot, the corresponding pAkt(S473) blot was incubated with stripping buffer after exposure to remove

50

antibodies, and was then re-probed with anti-Akt. Each condition is represented with samples from 3
independent experiments. (B) Quantitative analysis of Akt activation level (blue) and EGFR/ErbB3
chimera expression level (grey), calculated from all 3 independent experiments. Band intensities
(EGFR/ErbB3, pAkt, Akt) were determined from Western blots using ImageJ software. In each
independent experiment, Akt activation levels were calculated as the ratio of the pAkt(S473) and Akt band
intensities. EGFR/ErbB3 expression levels were also normalized by total (endogenous) Akt levels. Values
from all 3 experiments were combined to calculate the final means and standard deviations. Error bars
represent one standard deviation. Significance is shown as the difference of ligand induced Akt activation
levels between CHO cells transfected with wildtype or V836R/L839Q doubly mutated EGFR/ErbB3
chimera (p < 0.01).

For reasons that are not clear, the V836R/L839Q double mutant also consistently
expresses at lower levels than either full length wildtype ErbB3 or the EGFR/ErbB3
chimera. However, the effect is smaller than a factor of two, so this is unlikely to explain
the reduced Akt activation that we observe – which does not appear to correlate with
receptor expression level in this range in our studies in Figures 1.11-1.13. The lack of
dependence of Akt activation on receptor expression levels in Figure 1.11, for example,
suggests that the amount of ErbB3 in our CHO cell studies is over-saturating in all cases.
Indeed, the V836R or L839Q single mutants maintain normal Akt signaling ability
despite also displaying reduced expression levels. We therefore suggest that the ErbB3
V836R/L839Q double mutant has an intrinsic signaling defect. Importantly, this defect is
seen in both full length ErbB3 and the EGFR/ErbB3 chimera, despite the fact that the
extracellular domains of ErbB3 and EGFR have disparate dimerization properties (EGFR
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ectodomain prefers homodimer whereas ErbB3‘s only forms heterodimers), and therefore
the composition of ligand induced ErbB dimers should be very different in these two
cases. In the CHO cell experiments, even upon ligand stimulation the
autophosphorylation of ErbB3 could not be detected by Western blotting (data not
shown), again suggesting a lack of dimerization partners (eg. ErbB2) in these cells – as
anticipated from the literature. This contrasts with the BaF3 stable cell lines described in
Figure 1.10, which express high levels of both ErbB2 and ErbB3 and show robust ErbB2
and ErbB3 phosphorylation upon ligand stimulation in Western blots.
The fact that the V836R/L839Q double mutation compromises the downstream
signaling ability of ErbB3 TKD is surprising. This observation seems unlikely to reflect
a simple loss of ErbB3 kinase activity, since known kinase-defective variants (K723M,
K723R and V836A) retain the ability to activate Akt. (However, we cannot completely
rule out the possibility that the V836R/L839Q double mutation is required to reduce
ErbB3‘s kinase activity to a sufficiently low level to compromise its signaling in CHO
cells. Unfortunately, we have not been able to assess the kinase activity of
V836R/L839Q-mutated ErbB3 in vitro, since the recombinant kinase domain harboring
this pair of mutations aggregates during purification.) Also, the reduced Akt signaling
activity is unlikely to result from a failure of the mutated ErbB3 to trans-activate another
ErbB receptor present at low levels in CHO cells, since this effect shall only involve the
C-lobe of ErbB3 TKD, which should be unaffected by these mutations. Moreover, the
V836R/L839Q double mutation in ErbB3 did not change the ligand-induced ErbB2 or
ErbB3 autophosphorylation levels in BaF3 cells (Figure 1.10B). We therefore suggest
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that the V836R/L839Q double mutation influences downstream Akt signaling through
some other mechanism. If both mutations are required to disrupt the association between
the activation loop helix and helix C in Figure 1.8A&D, they may alter the TKD
conformation, which in turn might affect its interaction properties with downstream
signaling proteins.
1.5

Summary and Discussion of ErbB3 Studies

ErbB3 has been historically considered to have an inactive kinase domain, due to amino
acid changes at key positions when compared with ‗canonical‘ protein kinase domains.
We have shown that the kinase domain of ErbB3 does retain significant phosphoryl
transferase activity despite these sequence alterations, as evidenced by transautophosphorylation of the purified ErbB3 intracellular region in vitro. The observed
kinase activity appears to be about 1000-fold weaker than that seen for EGFR. The
ErbB3 kinase domain binds ATP with a KD of approximately 1.1 M, similar to (and
even stronger than) that reported for many other known active kinases. Using
commercially available kinase inhibitor libraries, we have shown that ErbB3 kinase is
poorly targeted by current inhibitors. We also describe a crystal structure of ErbB3 kinase
bound to an ATP analogue, which resembles the inactive EGFR and ErbB4 kinase
domains (but with a shortened C-helix). A conserved hydrophobic patch at the
beginning of the ErbB3 activation loop, involving side-chains from a small  helix in this
loop, appears to be responsible for holding the protein in an inactive-like conformation.
Mutations that disrupt this hydrophobic patch in EGFR are known to destabilize such
inactive conformation, causing hyper-activation of the kinase – and are oncogenic drive
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mutations in NSCLC. By contrast, equivalent mutations in ErbB3 appear to compromise
ErbB3‘s ability to activate downstream Akt signaling in cellular studies. Thus, the ErbB3
TKD has novel properties – beyond simply trans-activating neighboring ErbB kinases in
ligand induced heterodimer as proposed (Jura, Shan et al. 2009).
A key question is whether or not the kinase activity observed in vitro is sufficient
to mediate meaningful tyrosine phosphorylation in cells. The rate of ErbB3-ICD
autophosphorylation when clustered on vesicles containing DOGS-NTA-Ni was about
1000 fold slower than that seen for EGFR-ICD under similar conditions, and exogenous
peptide phosphorylation was negligible. Since the ErbB3 TKD is predicted not to form
the same asymmetric homodimers as seen for EGFR (Zhang, Gureasko et al. 2006), this
difference might simply reflect our failure to activate ErbB3 completely using this in
vitro approach. Alternatively, the maximum kinase activity of ErbB3 might indeed be
~1000 fold weaker (or more) than EGFR and other ErbB kinases. If so, might this
nonetheless be relevant for receptor signaling? There are several reasons to suspect so.
Activation of most RTKs involves initial ‗activating‘ trans-autophosphorylation
events that follow ligand-induced dimerization (Schlessinger 2000), which typically
increase the catalytic efficiency of the kinase by 150-1000 fold overall (Cobb, Sang et al.
1989; Favelyukis, Till et al. 2001; Till, Becerra et al. 2002; Furdui, Lew et al. 2006). The
resulting ‗full‘ kinase activation is required for the receptor to phosphorylate exogenous
substrates such as insulin receptor substrate-1 (IRS-1) and phospholipase-C (PLC)
(Furdui, Lew et al. 2006), but is clearly not necessary for the initial activating transautophosphorylation steps (which are mediated by the much weaker unactivated kinase).
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Indeed, literature estimates suggest that the initial trans-phosphorylation events
responsible for activation of the insulin receptor and FGF receptor – mediated by a kinase
domain that has not been autophosphorylated – involve kinases that are no more active
than ErbB3 in our assays, which are strong arguments as to why the weak kinase activity
of ErbB3 might be sufficient to promote (maybe transiently) receptor transautophosphorylation within RTK dimers (such as ErbB2/ErbB3 heterodimers), which can
be crucial for signaling in certain cellular contexts.
The weak kinase activity of ErbB3 could be clinically relevant in cases where this
receptor is implicated in mechanisms of resistance to agents that target other ErbB family
members (Baselga and Swain 2009). ErbB3 signaling has been found to be important in
resistance to gefitinib in NSCLC that arises from MET amplification (Engelman,
Zejnullahu et al. 2007), and escape of ErbB2-overexpressing cell lines from growth
inhibition or suppression by ErbB kinase inhibitors (Sergina, Rausch et al. 2007). Efforts
to inhibit ErbB3 in these (and other) settings have focused on the use of therapeutic
antibodies to date (Baselga and Swain 2009). However, if the kinase activity of ErbB3
plays a role in the mechanism by which cancer cells bypass current ErbB-targeted cancer
treatments, it will be an attractive target for clinical intervention. The development of
small molecules that bind specifically to ErbB3‘s ATP-binding site would thereby
provide useful therapeutic leads. Even if the kinase activity of ErbB3 is not signalingrelevant, certain compounds of this class may be capable of stabilizing ErbB3 TKD
conformations that do not support signaling (eg. mimic the effects of the V836R/L839Q
double mutation described above), and therefore have therapeutic applications.
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Further testing of the importance of ErbB3‘s weak kinase activity will require
approaches that have not been described here. In the field of pseudokinases, the key
question is that of whether the (pseudo) kinase domain communicates with other aspects
of the signaling pathway using kinase activity per se or through protein-protein
interactions that may be regulated by extracellular ligand binding. Distinguishing
between these two possibilities is a difficult challenge. Using the mutation-based
approach employed here, it is impossible to determine whether a kinase-inactivating
mutation also alters the conformation. Thus, a mutation that aims to impair kinase
activity might actually exert its negative effects on signaling by altering pseudokinase
conformation. To circumvent this problem, we have exerted significant effort in
developing approaches to inhibit ErbB3‘s kinase activity pharmacologically. We chose
to use an approach employing analog-sensitive alleles that was pioneered by the
laboratory of Kevan Shokat (Bishop, Kung et al. 1999; Alaimo, Shogren-Knaak et al.
2001; Elphick, Lee et al. 2007). The basic idea is that one mutates the gatekeeper residue
in the kinase of interest in order to render it sensitive to ‗bumped inhibitors‘ developed by
the Shokat group. If signaling is reconstituted using such an analog-sensitive allele
(T768G in ErbB3), the available bumped inhibitors can be used as specific inhibitors to
investigate the importance of its kinase activity. Our experiences with this approach are
summarized in Appendix 2, in order to document the technical problems experienced. In
brief, we were able to apply the allele-sensitive analog approach in pilot studies with
EGFR – as has also been achieved by Shokat and colleagues. However, signaling by the
variant of ErbB3 expected to be analog sensitive (T768G) did not appear to be effectively
inhibited by any available bumped inhibitors. (We were able to detect some effects of the
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bumped inhibitors in cells, but the concentrations required to do so were sufficiently high
that off-target effects are highly likely.) However, the lack of signaling response of
analog sensitive ErbB3 to bumped inhibitors may be a consequence of the fact that
ErbB3‘s kinase is relatively insensitive to broad-specificity kinase inhibitors (as
mentioned in discussion of Figure 1.6), and therefore the affinities of the bumped
inhibitors are not strong enough for ErbB3 kinase. In collaboration with the Shokat
laboratory, we are now working to develop inhibitors that will specifically block the
ErbB3 ATP-binding site with high affinity. These studies are still at an early stage, and
further work to assess the role of ErbB3‘s kinase activity in cell signaling awaits progress
with these compound development efforts.
Although kinase-impaired ErbB3 mutants showed no apparent signaling defect in
our cellular studies, our data do not necessarily rule out the possibility that ErbB3 can
function as a kinase in cells. Indeed, the readout of our assay is limited to essentially a
few specific tyrosine phosphorylation sites within the complex ErbB signaling network.
A more general, proteomic approach such as SILAC might be required in order to study
specific effects of disrupting ErbB3 kinase activity. Due to limited time and mass
spectrometry resources, I have not been able to explore this approach. Another useful
approach – for which my initial efforts are outlined in Appendix 2 – would be to use an
analog-sensitive ErbB3 allele and bumped ATP in order to identify ErbB3 substrates as
described by the Shokat group (Alaimo, Shogren-Knaak et al. 2001; Elphick, Lee et al.
2007). Even at the absence of such data, we can formulate some reasonable hypotheses
regarding ErbB3 kinase activation in cells:
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1) ErbB3 might need other cellular factors to become fully activated in the cell,
and this would not be captured in our simplified heterodimer system in BaF3/CHO cells
or in our in vitro system. For example, a phenomenon of this sort might be relevant for
MET/ErbB3 cross-talk, with MET signaling providing such activating factors.
2) ErbB3 kinase may have a (uncharacterized) specific substrate preference,
which is overlooked in my cellular studies. For example, it may be subject to a substrateassisted activation mechanism, which is not uncommon in other enzymes (Dall'Acqua
and Carter 2000). Such a mechanism could be particularly interesting in the case of
ErbB3 kinase. Based on the structure, the only ―canonical‖ catalytic element missing in
the ErbB3 kinase active site is a carboxylate group that is typically found on the
conserved Asp (substituted by an Asn in ErbB3) proposed to function as a catalytic
general base. A kinase substrate that provides such a carboxylate group at the right
position might conceivably complement such a deficiency, and thus become an optimal
substrate for ErbB3 kinase.
Zhang et al. (Zhang, Gureasko et al. 2006) previously argued based on sequence
comparisons that the ErbB3 TKD should be able to participate as an ‗activator‘ in
allosteric activation of the EGFR kinase domain within the context of an asymmetric
dimer, due to the similarity of its C-lobe to that of EGFR-TKD, but not as the ‗receiver‘
that becomes activated (because of substantial change in the ErbB3 N-lobe comparing to
that of other ErbBs). Jura et al. (Jura, Shan et al. 2009) reported an ErbB3-TKD674-1001
structure (PDB ID 3KEX) that is essentially identical to the structure described here, and
have confirmed the ability of ErbB3-TKD to function as an allosteric activator of the
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EGFR kinase domain in vitro. The structural differences in the N-lobe – including the
shortened C helix described above – reinforce the argument that ErbB3-TKD cannot be
activated by the same types of asymmetric dimer interactions thought to activate EGFR,
ErbB4 and ErbB2 in heterodimeric complexes. If the ErbB3 TKD can function as a
‗receiver‘ kinase in ErbB receptor dimers, it must do so though mechanisms that are quite
different from those described for EGFR (Zhang, Gureasko et al. 2006) and ErbB4 (Qiu,
Tarrant et al. 2008).
A common argument for ErbB3 not being a physiologically relevant active kinase
is that the N-lobe of ErbB3 TKD is different from that of other ErbBs, suggesting that it
cannot function as a receiver kinase in the asymmetric dimer (and thus become activated).
However, this argument implies that ErbB2 kinase is sufficiently active to carry out all
the tyrosine phosphorylation of both C-tails in the heterodimer – of ErbB3 (in trans) and
ErbB2 (in cis). Given also that ErbB2 is an orphan receptor (and only forms
heterodimers with other ErbBs), ErbB2 has no need to function as an activator kinase in
the asymmetric dimer if it can mediate all phosphorylation by itself when activated by the
other kinase in the heterodimer – which in turn suggests that the C-lobe interface of
ErbB2 kinase does not have to be evolutionarily conserved. In fact, the ErbB2 C-lobe
interface is highly conserved for asymmetric dimer formation, suggesting that, in the
heterodimer with ErbB2, the other ErbB kinase also needs to be activated by ErbB2.
Therefore, in the case of ErbB heterodimer involving ErbB3, ErbB3 kinase activity may
be required for optimal signaling, although it may function through a different
mechanism due to an altered N-lobe of ErbB3 TKD.
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So far we have been discussing the possibility that ErbB3 functions as a kinase in
the cell. Our cellular studies have also shown that, even though kinase-inactivating
mutations within ErbB3 TKD have no effect on its autophosphorylation or activation of
Akt pathway, the V836R/L839Q double mutation compromises its ability to mediate
neuregulin-induced Akt activation (but not levels of ligand-induced ErbB
autophosphorylation). The finding that disrupting the hydrophobic patch between the
activation loop helix and C helix within the ErbB3 kinase domain reduces downstream
signaling activation provides supporting evidence for the hypothesis that ErbB3 TKD
plays additional signaling roles beyond simply trans-activating neighboring ErbB kinases
in ErbB3-containing heterodimers. Since the Akt pathway is directly involved in the
development of cancers and their drug resistance via ErbB3 (Engelman, Janne et al. 2005;
Sergina, Rausch et al. 2007; Castaneda, Cortes-Funes et al.), understanding how the
ErbB3 kinase domain affects these signaling pathways should provide useful clues for
developing therapeutic approaches in cancer. Unfortunately, my studies do not provide a
clear view of the degree to which these changes affect ErbB3 kinase activity or ATP
binding ability, since introducing these mutations – together or individually – into
recombinant ErbB3 ICD protein (over-expressed in Sf9 insect cells) impairs protein
stability, resulting in protein aggregation during protein purification and an inability to
perform in vitro assays. Additional cellular studies are needed to uncover the molecular
mechanism underlying ErbB3 TKD‘s regulation of downstream Akt signaling activation.
Based on our CHO cell study it seems likely that ErbB3 kinase domain acts as a
scaffolding protein that may allosterically regulate downstream signaling. Such function
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is not usual, even for highly active kinases. For example, recent studies of Akt protein
itself have revealed that, in addition to catalysis, its kinase domain can function as a
protector for phosphorylated residues upon binding to ATP or ATP-competitive
inhibitors (Chan, Zhang et al.; Lin, Lin et al.) – i.e. a scaffolding function. Binding of
ATP (or inhibitor) stabilizes Akt kinase domain in a restricted conformation, which
brings its phosphorylated T308 and S473 residues close to the kinase domain surface and
shields them from phosphatases, whereas binding of ADP has the opposite effect
(facilitating dephosphorylation) (Lin, Lin et al.). A similar function may exist in ErbB3
kinase domain (the ‗inactive‘ conformation with ATP bound protects the phosphortyrosine to be hydrolyzed), which could explain the observed cellular effect of
V836R&L839Q double mutation.
Several earlier studies have suggested a non-canonical role for the ErbB3 kinase
domain, reminiscent of proposed ‗scaffold-like‘ functions for its pseudokinase domain:
1) Using a yeast two-hybrid approach, Yoo et al. measured the interaction
between ErbB3 ICD and the p85 unit of PI3K using a β-galactosidase reporter assay (Yoo
and Hamburger 1998). Intriguingly, wildtype rat ErbB3 (which retains its catalytic base
aspartate at D815 - unlike human ErbB3) generates low output signal, suggesting a lack
of ErbB3 tyrosine phosphorylation. However, a D815N rat ErbB3 mutant facilitates the
interaction and increase the assay output by 26 fold. Curiously, further mutating the
conserved key lysine in the ATP binding site (i.e. rat ErbB3 K723A/D815N double
mutant) abolishes this output increase. Although it is unclear whether the increase of
signal is caused by ErbB3 kinase activity or change of conformation, this result implies a
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functional role of Asn815 (instead of Asp) in ErbB3 TKD to modulate PI3K interaction –
perhaps through a scaffolding function.
2) In a study by Engelman et al. (Engelman, Janne et al. 2005), CHO cells
transfected with wildtype EGFR showed sustained Akt activation even after 4 hours of
EGF stimulation, whereas the long term phosphoAkt signal was abolished in CHO cells
transfected with EGFR L858R (equivalent to ErbB3 V836R) activating mutant. This
result is reminiscent of our CHO cell studies, in which the ErbB3 V836R/L839Q double
mutant shows compromised ability to activate Akt pathway compared to wildtype ErbB3.
In both cases, a specific conformation change accompanied with the mutations may
disrupt the ability of ErbB protein (EGFR and ErbB3) to relay ligand stimulation to
downstream signaling.
In additional to the ErbB3 kinase described here, the signaling scaffold function
has been proposed in many other pseudokinases, such as STRAD proteins to the kinase
domain of LKB1, KSR for MAP kinase signaling, CASK in the synaptic protein complex,
and the autonomous regulation of JAK2‘s pseudokinase domain to its upstream tyrosine
kinase domain (summarized in (Boudeau, Miranda-Saavedra et al. 2006)). Intriguingly,
all these pseudokinases have been reported to possess either ATP binding ability (for
STRAD (Boudeau, Scott et al. 2004)) or kinase activity (for KSR1 (Hu, Yu et al. 2011;
Shi and Lemmon 2011), CASK (Mukherjee, Sharma et al. 2008) and JAK2
(Bandaranayake, Ungureanu et al. 2012)), although the exact roles of such functions are
often unclear. Further in-depth analysis is required to provide us with a better picture of
the role of pseudokinases such as ErbB3‘s.
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1.6

Experimental Procedures for Chapter 1
Materials and Reagents. Mant-ATP (2'-(3')-O-(N-methylanthraniloyl)adenosine

5'-triphosphate) was purchased from Invitrogen (Cat.# M-12417). 1, 2-dioleoyl-snglycero-3-([N(5-amino-1-carboxypentyl)iminodi-acetic acid]succinyl} nickel salt
(DOGS-NTA-Ni) was purchased from Avanti Polar Lipids. Primary antibodies
mentioned here include: pY20 antibody (BIOMOL), anti-His5 antibody (QIAGEN), antiErbB2 pTyr877, anti-ErbB3 pTyr1289, anti-Akt and anti-pAkt(Ser473) antibodies (Cell
Signaling), anti-ErbB2 Ab8 and anti-ErbB3 Ab7 antibodies (NeoMarker/LabVision).
Neuregulin 1β was purchased from R&D Systems Inc.
Protein Expression and Purification. DNA fragments encoding the relevant
regions of the human ErbB3 intracellular domain (ErbB3-ICD665-1323) or tyrosine kinase
domain (ErbB3-TKD665-1001 and ErbB3-TKD648-1001) with an amino-terminal hexahistidine tag were subcloned into the pFastBac1 vector (Invitrogen) to generate
corresponding baculoviruses using the Bac-to-Bac expression system (Invitrogen).
Spodoptera frugiperda Sf9 cells were infected with the respective baculoviruses for 3
days, and cells were collected and resuspended in buffer containing 20 mM HEPES pH
8.0, 300 mM NaCl, 5% glycerol, 5 mM 2-mercaptoethanol and a protease inhibitor
cocktail (Roche). ErbB3 proteins were affinity purified using Ni-NTA beads (Qiagen),
followed by anion exchange chromatography with a UnoQ1 column (Bio-Rad) in 20 mM
Tris pH8.0, 5% glycerol and 1 mM DTT (eluting with a linear gradient from 120 mM to
1 M NaCl). ErbB3-containing fractions were concentrated and subjected to size exclusion
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chromatography using a Superdex 200 column (GE Healthcare) equilibrated with 20 mM
Tris pH 8.0, 200 mM NaCl, 5% glycerol and 1 mM DTT.
Analysis of Autophosphorylation by Western Blotting. Vesicles containing
DOGS-NTA-Ni at 5-10 % (mole/mole) in a background of dioleoylphosphatidylcholine
(Sigma) were prepared as described (Zhang, Gureasko et al. 2006). Vesicles (50-150 M
total lipid) were incubated with ErbB3 proteins at the concentrations noted in the legend
to Figure 1.3 in 100 mM MOPS pH 7.4, containing 200 mM NaCl, 5 % glycerol, 1 mM
ATP, 5 mM MgCl2, 2 mM MnCl2, and 0.1 mM DTT for 30 min at 25˚C, and the
reactions were stopped by adding 50 mM EDTA and SDS-PAGE gel-loading buffer.
Proteins were subjected to electrophoresis and transferred to nitrocellulose for Western
blotting. Blots were probed with the indicated primary antibodies, and detection was
accomplished using an HRP-conjugated anti-mouse (or rabbit) antibody (Amersham) and
enhanced chemiluminescence.
Mant-ATP Binding Assay. Binding assays were carried out in 20 mM Tris pH
8.0, containing 200 mM NaCl, 5 % glycerol, 1 mM DTT, 5 mM MgCl2 and 0.6 μM
Mant-ATP, with varying amount of ErbB3648-1001 protein. Fluorescence measurements
were taken in triplicate using a Tecan SAFIRE II plate reader, with excitation wavelength
of 280 nm and emission wavelength of 450 nm (5 nm bandwidth for both) to monitor
FRET between protein and bound mant-ATP.
Crystallization and Structure Determination. Purified ErbB3-TKD665-1001 was
concentrated to 6 mg/ml and incubated with 5 mM MgCl2 and 1 mM AMP-PNP (Sigma).
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Crystals were obtained using the hanging-drop method at 21°C by mixing the protein
with an equal volume of reservoir solution (50 mM MOPS pH 7.4, 27 % (w/v) PEG8000,
0.17 M (NH4)2SO4 and 15% glycerol). Needle-like crystals appeared within 2 days and
were frozen in liquid nitrogen directly from the mother liquor. Diffraction data were
collected at the Argonne Advanced Photon Source (beamline GM/CA CAT) and
processed with the program HKL2000 (Otwinowski and Minor 1997). The structure was
solved using molecular replacement (MR) using the program Phaser (CCP4
(Collaborative Computational Project Number 4) 1994) with the inactive EGFR (V924R)
TKD structure (PDB code 2GS7) (Zhang, Gureasko et al. 2006) as the search model. The
program Coot (Emsley and Cowtan 2004) was used for model building, and refinement
employed the programs REFMAC (CCP4 (Collaborative Computational Project Number
4) 1994) and CNS (Brünger, Adams et al. 1998). TLS refinement (Winn, Isupov et al.
2001) was employed in the later stages of refinement, using REFMAC (CCP4
(Collaborative Computational Project Number 4) 1994), with anisotropic motion tensors
refined for each lobe of the kinase domain. Structure figures were generated using PyMol
(DeLano 2002).
Cellular Studies. For studies with BaF3 cells, BaF3 cells were maintained in
RPMI 1640 medium containing 10% FBS, 10mM HEPES, 2mM sodium pyruvate and
1ng/ml IL3. To generate each stable BaF3 cell line co-expressing ErbB2 and ErbB3, a
pIRES plasmid with the relevant full length ErbB3 at site A and full length ErbB2 at site
B (after IRES) was introduced into BaF3 cells using electroporation with a BTX 600
instrument. Briefly, 4x106 cells were incubated with 40 µg DNA and electroporated at
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1500 µF capacitance, 240 voltage and R10 resistance. 48 hours post-electroporation,
G418 was added to a final concentration of 1mg/ml in the medium to select (over 10 days)
for cells harboring the plasmid. Cells were then sorted for high ErbB2 expression using
FACS and PE-labeled anti-HER2 antibody (Becton Dickinson). For autophosphorylation
experiments, BaF3 cells were serum starved for 6 hours, then washed and resuspended in
cold PBS at a density of 1x107 cells/ml. Cells were then stimulated with neuregulin1β
(50ng/ml) for 10 min on ice. Cells were lysed in RIPA buffer (25 mM Tri-HCl pH 7.5,
150 mM NaCl, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% SDS) containing 1
mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM NaF, 5 mM Na2MoO4, and 0.2
mM Na3VO4, and debris was pelleted by centrifugation. All glycoproteins in the lysate
were then collected by incubating the lysate with concanavalin A beads (GE Healthcare,
40ul beads for 107 cells) for 2 hours at 4 ˚C. Beads were then washed, resuspended in
RIPA buffer (final volume of 100ul), and added 3x RSB with 5% BME and EDTA to a
final concentration of 50mM. Samples were then boiled for Western blotting with
indicated antibodies.
For Akt activation experiments, CHO cells were maintained in Hank‘s F12 media
containing 10% FBS, 2 mM L-glutamine and 1.5 g/L sodium bicarbonate. For transient
transfection, parental CHO cells were seeded at 4x105 cells/well in 6-well plates. 24
hours after seeding, cells were transfected with indicated pcDNA3.1-ErbB3 full-length or
pRc/CMV-EGFR-ErbB3 chimera constructs using FuGENE transfection reagent (1.5 µg
DNA and 6 µl reagent per well). 24 hours after transfection, medium was removed and
replaced with serum-free medium overnight. Cells were then stimulated with
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neuregulin1β (or PBS as negative control) for 10-30 minutes, then lysed in RIPA buffer
containing 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM NaF, 5 mM
Na2MoO4, and 0.2 mM Na3VO4. Lysates were then subjected to Western blotting with
indicated antibodies. For blots of total Akt, the corresponding pAkt(S473) blot was
incubated with stripping buffer after HRP signal development to remove pAkt antibodies,
and was then re-probed with anti-Akt antibodies.
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Chapter 2
Characterization of Derailed-Wnt Interactions
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Ryk/Derailed family receptor tyrosine kinases (RTKs) are membrane signal transducers
thought to mediate signaling induced by extracellular Wnt proteins. While developmental
studies have characterized the indispensable roles of Ryk/Derailed family RTKs in cell
patterning and differentiation, especially during neuronal development, few studies have
attempted to uncover the molecular mechanisms of their signaling and ligand recognition.
Utilizing biophysical methods, my study aims to understand the molecular interactions
between Ryk/Derailed family RTKs and Wnt ligands, using Drosophila Derailed –
DWnt5 as a model system.
2.1

Overview of Ryk/Derailed – Wnt Signaling Pathway

2.1.1

Introduction to Wnt proteins and Wnt Pathway

Wnts, named after Wg (wingless) and Int (Integration 1), are a family of highly
conserved, secreted proteins containing a characteristic Wnt domain that is comprised of
~330 amino acids with a characteristic distribution of 24 cysteine residues. A total of
nineteen Wnt family proteins have been identified in the deduced mammalian proteome.
They play diverse roles in embryonic development and adult homeostasis, including
segment polarity (Baker 1987) and neural tube development (Ikeya and Takada 1998)
during embryogenesis and adult limb formation during metamorphosis (Yokoyama,
Maruoka et al.). Wnt proteins are typically lipid modified, rendering the proteins
hydrophobic (Willert, Brown et al. 2003; Takada, Satomi et al. 2006; Kurayoshi,
Yamamoto et al. 2007).
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In canonical Wnt signaling, the Wnt – β-catenin – TCF axis plays a central role.
In the absence of Wnt signaling, β-catenin is constantly phosphorylated in a protein
complex formed by Axin/APC/casein kinase 1 (CK1)/glycogen synthase kinase 3
(GSK3). Phosphorylated β-catenin is then ubiquitinated and degraded by proteasome.
The binding of Wnt proteins to the cysteine-rich domain (CRD) of Frizzled receptors
(their best known cell surface receptors) and LRP 5/6 co-receptors leads to recruitment of
Dishevelled (Dvl) protein through its PDZ domain to the intracellular tail of the Frizzled
receptor and subsequent phosphorylation of LRP6. Phosphorylated LRP protein on the
membrane then recruits the Axin complex, thus freeing β-catenin protein from
degradation in the cytosol. Accumulated β-catenin then translocates into the nucleus and
binds to DNA-bound TCF transcription factors, which in turn initiates transcription of
genes that are controlled by TCF promoter (Figure 1A, left) (Logan and Nusse 2004;
MacDonald, Tamai et al. 2009; Clevers and Nusse 2012).
Very recently, a crystal structure of Xenopus Wnt8 (XWnt8) in complex with the
CRD of mouse Frizzled-8 (mFz-8) was reported (Figure 2.1B) (Janda, Waghray et al.).
The CRD of mouse Frizzled-8 displays a mostly α-helical structure as described before
(Dann, Hsieh et al. 2001). XWnt8 comprises a large N-terminal region that is mostly αhelical (with four short β strands formed as a sheet on one side) and a smaller C-terminal
region that contains two long β strands in a hairpin-like configuration. The crystal
structure also revealed Ser207 of XWnt8 (equivalent to Ser868 of DWnt5) as a lipidation
site. XWnt8 binds to mFz-8 CRD through two separate loop regions. The first binding
region, located on the N-terminal side of XWnt8, mainly uses the palmitoyl lipid moiety
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(PAM in Figure 2.1B) to engage a hydrophobic groove on the CRD. The second binding
region, which is located in between the two long β strands on the C-terminal side of
XWnt8, consists of a long loop and is thought to contribute to selectivity of Wnt binding
to CRDs from different Frizzled receptors. However, it is yet unclear from this structure
how binding of Wnt ligand leads to signaling through Frizzled receptors.
In addition to the canonical Wnt signaling, Wnt proteins also participate in the
orientation of planar cell polarity (PCP) through signaling to c-Jun N-terminal kinase
(JNK) (Wang 2009), and control of cell migration through the activation of
heterotrimeric G proteins that leads to increased level of intracellular Ca2+ and signaling
by calcium dependent kinases (De 2011) (Figure 1A, right).
Increasing evidence has shown unequivocally that the canonical, PCP, and
Wnt/Ca2+ pathways are only some of the many signaling events initiated by Wnt binding,
and the specific cellular response for any Wnt ligand reflects the combined actions of a
diverse set of Wnt receptors present on the cell surface (van Amerongen, Mikels et al.
2008). In addition to the ten Frizzled receptors in mammals, the RTKs Ryk and Rors
have been shown to act as Wnt receptors on the cell surface that mediate Wnt signaling
(Figure 1A). Ror1 and Ror2 contain CRD domains that are related to those in Frizzleds.
On the other hand, Ryk/Drl lack a CRD-related domain for Wnt binding. Instead, they are
thought to bind Wnts through their extracellular WIF domains, which are homologous to
human Wnt Inhibitory Factor-1 (hWIF-1) protein.
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Figure 2.1: Overview of Wnt signaling. (A) Illustration of canonical and non-canonical Wnt signaling
(adapted from (Katoh and Katoh 2007)). (B) Crystal structure of Xenopus Wnt8 (XWnt8) in complex with
the cysteine rich domain (CRD) of mouse Frizzled-8 (mFz-8) (PDB: 4F0A) (Janda, Waghray et al. 2012).
The lipid moiety of XWnt8 is labeled PAM.
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2.1.2

Introduction to Ryk/Derailed Family Receptor Tyrosine Kinases

Ryk (Related to tYrosine Kinases) is a protein with a single transmembrane domain that
belongs to the vertebrate RTK family, first isolated in the early 1990s using PCR with
degenerate primers (Hovens, Stacker et al. 1992; Yee, Bishop et al. 1993). Ryk orthologs
are also present in invertebrate, such as Derailed in Drosophila melanogaster and LIN-18
in C. elegans. Ryk and its invertebrate orthologs are characterized by an extracellular
WIF (Wnt Inhibitory Factor) domain (see below) and an intracellular pseudokinase
domain (Figure 2.2).
Ryk is expressed in various mammalian tissues during both embryogenesis and
adulthood (Halford, Oates et al. 1999). Homozygous Ryk-null mice display distinctive
development defects, including a shortened craniofacial region and diminished limbs
(Halford, Armes et al. 2000). These morphological features are similar to the symptoms
observed in mice lacking members of the EphB family of RTKs (Bush and Soriano 2010),
implying signaling crosstalk or collaboration between the Ryk and EphB classes of RTKs.
Accordingly, Ryk has been shown to co-immunoprecipitate with both EphB2 and EphB3
(Halford, Armes et al. 2000; Trivier and Ganesan 2002; Kamitori, Tanaka et al. 2005). In
addition, overexpression of Ryk has been reported to cause transformation of NIH3T3
cells, leading to their tumorigenicity when injected into nude mice (Katso, Manek et al.
1999).
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Figure 2.2: Domain organization of Ryk and Derailed (mature protein with signal peptide cleaved). WIF:
Wnt Inhibitory Factor domain; S/T Rich: Serine/Threonine rich segment; PTK: Protein Tyrosine Kinase
domain.
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The best characterized Ryk ortholog in invertebrate is Derailed (Drl) in D.
melanogaster. Drl protein has the same domain organization as human Ryk (Figure 2.2),
with 34% sequence identity between their WIF domains and 48% sequence identity
between their pseudokinase domains. Drl was first isolated based upon its function in
neuronal axon pathfinding (Callahan, Muralidhar et al. 1995). Abnormal muscle
attachment to epidermis was also observed in drl knockout flies (Callahan, Bonkovsky et
al. 1996). At the same time, another research group independently identified Drl as the
gene responsible for the learning and memory deficits displayed in fly linotte mutants
(Dura, Taillebourg et al. 1995).
Signaling by receptor tyrosine kinases is known to be initiated through their
stimulation by extracellular ligands (Lemmon and Schlessinger 2010). Ryk and Derailed
are no exceptions to this rule. Owing to the presence of a WIF-homolgous domain in their
extracellular regions, Ryk and Derailed have been characterized as potential receptors for
Wnt ligands (to which human WIF-1 protein is known to bind), and a variety of studies
have shown that they contribute to the complex regulation of tissue development by Wnt
signaling.
2.1.3

Introduction to Human Wnt Inhibitory Factor-1 (hWIF-1)

Human WIF-1 is a secreted protein known to bind various Wnt proteins, and is thought to
inhibit their signaling by preventing Wnts from binding to their cell-surface receptors.
hWIF-1 is composed of an N-terminal signal sequence and a WIF domain followed by
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five EGF repeats and a short C-tail. When overexpressed in Xenopus laevis embryos,
hWIF-1 causes their dorsalization or anteriorization, mimicking phenotypes observed
when Xenopus Wnt8 (XWnt8) signaling is blocked (Hsieh, Kodjabachian et al. 1999).
hWIF-1 was also found to block the ability of overexpressed XWnt8 to induce axis
induction in a dose-dependent manner, and the WIF domain alone is as effective in
inhibiting this process as full-length hWIF-1 (Hsieh, Kodjabachian et al. 1999). A total of
six mammalian Wnt proteins have been reported to associate with hWIF-1 (Malinauskas,
Aricescu et al. 2011). In vitro binding studies have been carried out to map the regions of
WIF-1 responsible for Wnt binding (Malinauskas, Aricescu et al. 2011). Full-length WIF1 binds tightly to Wnt3a with KD of 60 nM. Both WIF domain and EGF repeats appear to
contribute to Wnt-association: the WIF domain alone binds Wnt3a with a KD of 3.4 M,
whereas a fragment containing the EGF repeats alone binds Wnt3a with a KD of 0.9 M
(Malinauskas, Aricescu et al. 2011).
NMR and X-ray crystallographic studies have provided structural insights into the
WIF domain (Liepinsh, Banyai et al. 2006; Malinauskas, Aricescu et al. 2011): the WIF
domain adopts an overall immunoglobulin-like fold, with nine beta strands and two short
alpha helices (Figure 2.3 A&B). Interestingly, both studies have reported WIF binding to
hydrophobic detergent or lipid. The NMR-based study reported tight binding of the
detergent Brij-35 between the second beta-strand and second alpha helix of the WIF
domain (Liepinsh, Banyai et al. 2006; Malinauskas, Aricescu et al.). In the crystal
structure, the alkyl-chains of a phospholipid were found to penetrate into the core of WIF
domain from the opening between the two alpha helices (Malinauskas, Aricescu et al.
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2011). Given the fact that Wnts are typically lipid-modified, these observations raised the
intriguing possibility that the WIF domain binds to Wnts by recognizing their lipid
moiety as well as regions of the Wnt protein itself. However, the region(s) on the WIF
domain that are directly responsible for Wnt binding have not yet been identified
experimentally.

Figure 2.3: Reported structures of human Wnt Inhibitory Factor -1 (hWIF-1). (A) NMR structure of WIF
domain of hWIF-1 with no lipid (PDB: 2D3J) (Liepinsh et al. JMB 2006). (B) Crystal structure of WIF
domain of hWIF-1 with DOPC bound (PDB: 2YGN) (Malinauskas, Aricescu et al. 2011).
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2.1.4

Ryk/Drl Interact with Wnts and Mediate Wnt Signaling

The WIF domain of human Ryk contains about 130 amino acids and shares 23%
sequence identity to hWIF-1 (Figure 2.4A). Lu et al. (Lu, Yamamoto et al. 2004) have
demonstrated that the Ryk WIF domain co-immunoprecipitates with Wnts (Wnt-1 or
Wnt-3a), and that overexpression of Ryk increases Wnt-induced TCF-driven transcription
in 293T cells. Conversely, RNAi knockdown of Ryk expression abolishes TCF pathway
activation by Wnts. Ryk siRNA also causes a reduced level of Wnt3a-induced neurite
outgrowth in dorsal root ganglion (DRG) explants (Lu, Yamamoto et al. 2004). Later
studies of Ryk-Wnt signaling have focused mainly on its effects in neuronal development.
Schmitt et al. examined the effect of Ryk-mediate Wnt3 signaling on retinal ganglion
cells (RGCs) of chick (Schmitt, Shi et al. 2006), and showed that Ryk mediates a Wnt3induced axonal repulsion (inhibitory) response in neuron explants, which could be
inhibited by a specific anti-Ryk serum. By contrast, Frizzleds mediate an axonal
attraction response – which is thought to collaborate with repulsive Ryk signaling in
retinotectal topographic mapping (Schmitt, Shi et al. 2006). Similar Wnt-repulsive effects
of Ryk have also been reported by other studies in Ryk knockout mice (Keeble, Halford
et al. 2006) and in cultured neurons treated with anti-Ryk antibodies (Liu, Shi et al. 2005).
Since Wnts are typically distributed in a local concentration gradient in developing
organisms, the differential responses of Ryk-expressing and Frizzled-expressing neurons
presumably contribute to the formation of intricate neuron topographic patterning.
Recently, Ryk has also been implicated in cell fate determination of neural progenitor
cells (NPCs); knocking out Ryk from NPCs switches neural differentiation towards
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oligodendrocyte neurons, whereas re-introducing Ryk reverses this preference and
instead promotes differentiation towards GABAergic neuron (Li, Hutchins et al. 2009).

Figure 2.4: Sequence alignments of WIF domains. (A) Alignment of WIF domains in Drosophila Derailed,
human Ryk and human Wnt Inhibitory Factor -1. (B) Alignment of WIF domains in Drosophila Derailed,
Drosophila Doughnut, Drosophila Derailed-2 and human Ryk. Alignments are generated using ClustalW
and colored using JalView (Clustalx color scheme).
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The Drosophila melanogaster Ryk ortholog, Drl, has been shown to mediate
signaling by Drosophila Wnt5 (DWnt5), an ortholog of human Wnt5s (hWnt5).
Extensive studies have characterized Drl-DWnt5 mediated axon pathfinding in the
Drosophila embryonic central nervous system (CNS). In the Drosophila ventral nerve
cord, many neurons need to project axons across the midline to the opposite side of the
CNS via either the anterior commissure (AC) or posterior commissure (PC). Autonomous
expression of the Drl receptor guides a subset of axons to project through the anterior
commissure (rather than the posterior commissure) of each segment, and embryonic
neurons in flies lacking Drl showed defects in choosing the correct crossing path (hence
the name of the gene: derailed) (Callahan, Muralidhar et al. 1995; Bonkowsky,
Yoshikawa et al. 1999). Drl guides commissure choice through its interaction with
DWnt5, which is expressed predominantly on posterior commissural neurons and induces
repulsive signals in the Drl-expressing subset of neurons to promote their projection into
the anterior commissure (Fradkin, van Schie et al. 2004). Abolishing DWnt5 expression
undermines this guidance function of Drl, and causes a lack of separation between AC
and PC neurons when crossing the midline (Yoshikawa, McKinnon et al. 2003; Fradkin,
van Schie et al. 2004). Yoshikawa et al. also showed that a Drl ectodomain-Fc fusion
protein is able to accurately label the DWnt5 expression region in Drosophila embryos as
well as immunoprecipitate DWnt5, suggesting physical interaction between DWnt5 and
Drl (Yoshikawa, McKinnon et al. 2003). Drl-mediated DWnt5 signaling has also been
implicated in the patterning of olfactory receptor neurons (ORNs) in the Drosophila
antennal lobe (Yao, Wu et al. 2007; Sakurai, Aoki et al. 2009), in the development of

80

mushroom bodies (Moreau-Fauvarque, Taillebourg et al. 1998; Grillenzoni, Flandre et al.
2007), and in salivary gland migration (Harris and Beckendorf 2007).
In addition to Drl, two other Ryk homologs, Derailed-2 (Drl-2) and Doughnut
(Dnt), are also found in Drosophila (Figure 2.4B). The Drl and Drl-2 WIF domains share
44% sequence identity. Drl-2 was shown to be predominantly expressed in ORN axons
and to participate in development of the olfactory system – with functional
complementarity to Drl-DWnt5 signaling (Sakurai, Aoki et al. 2009). The Drl and Dnt
WIF domains share 64% sequence identity. Although Dnt has a distinct expression
pattern from that of Drl during embryogenesis, targeted overexpression of Dnt can
partially rescue embryonic muscle attachment defects in Drl null mutants. (Oates,
Bonkovsky et al. 1998)
2.1.5

The Pseudokinase Domains of Ryk/Drl Lack Kinase Activity but are Capable

of Signal Transduction
The signaling cascades triggered after Wnt binding to Ryk/Drl – which mediate the
repulsive signals outlined above – are unclear. The typical RTK activation scheme –
where ligand-induced receptor dimerization induces kinase activation and
autophosphorylation – is unlikely in this case. Despite having a highly conserved
intracellular kinase domain, Ryk/Drl are considered to have kinase-inactive
‗pseudokinase‘ domains, due to sequence alterations at several conserved residues that
are important for the activity of ‗canonical‘ kinases (summarized in (Halford and Stacker
2001)). Specifically,
81

1. The first glycine in the GxGxxG ‗P-loop‘ motif is altered (mostly replaced by
glutamine).
2. The DFG motif, thought to be a nexus of kinase regulation, is replaced by the
sequences DNA (in Ryk) or DSA (in Drl).
3. In the ATP binding pocket, a conserved alanine is replaced by a bulky
phenylalanine (in Ryk) or leucine (in Drl) in the VAIK motif, which may prevent
the accommodation of ATP substrate.
Several studies have attempted to address the question of whether Ryk/Drl can
function as kinases, and if not, how they might mediate signal transduction. Yoshikawa et
al. showed that a Drl mutant with the ―invariant‖ lysine in its kinase domain substituted
by alanine (K371A) – a mutation that greatly impairs activity of most kinases – is
indistinguishable from wildtype Drl in phenotypic rescue or gain-of-function assays
studying fly axon guidance and muscle attachment, suggesting that kinase activity is not
required for Drl-mediated signaling (Yoshikawa, Bonkowsky et al. 2001). In another
study (Taillebourg, Moreau-Fauvarque et al. 2005), the same presumed Drl kinase-dead
mutant was also shown to phenocopy wildtype Drl in inducing a gain-of-function
phenotype involving mushroom body defects in flies, despite a lower level of mRNA
expression. Similar to Drl, no kinase activity has been observed for Ryk kinase domain
(Trivier and Ganesan 2002). A TrkA extracellular – Ryk intracellular chimeric protein
also displayed lack of autophosphorylation upon NGF stimulation (Katso, Russell et al.
1999).
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In summary, so far no role in phosphotransfer catalysis has been observed for the
kinase domain of Ryk/Drl family RTKs. Yet the highly conserved cytoplasmic region
seems to be capable of signaling (Yoshikawa, Bonkowsky et al. 2001). In neuronal cells,
the Ryk intracellular domain (ICD) is thought to possess a Notch receptor like function.
After stimulation by Wnt binding, the Ryk ICD is cleaved off and translocates into the
nucleus, where it functions to promote neuronal differentiation (Lyu, Yamamoto et al.
2008; Lyu, Wesselschmidt et al. 2009). Indeed, Ryk ICD fused to a nuclear localization
signal (NLS) can functionally replace full-length Ryk in cell fate determination of neural
progenitor cells (Zhong, Kim et al. 2011). In studies with TrkA ECD/Ryk ICD chimeras,
the chimeric protein with the wildtype Ryk kinase domain is able to induce Erk
phosphorylation and activate MAPK pathway. Interestingly, mutating the invariant lysine
K334 to alanine in this case abolishes Erk phosphorylation (Katso, Russell et al. 1999).
Wouda et al. also showed that Src family kinases bind to and phosphorylate Drl, and
participate its downstream signaling (Wouda, Bansraj et al. 2008). Although these studies
have demonstrated a clear signaling capability of Ryk ICD, the mechanism of signal
transduction from Wnt binding to intracellular signaling activation remains unclear.
2.1.6

Biophysical Characterization of Drl-DWnt5 Interactions as a Model System

for Ryk/Drl Signaling
As summarized above, extensive studies have documented important roles of Ryk/Drl
RTKs in Wnt signaling and embryonic development, especially in axon pathfinding. In
sharp contrast, little is known regarding the molecular mechanisms of Wnt-Ryk/Drl
interactions or the resulting cellular signal transduction. Even the very first step of this
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signaling pathway – binding of Wnts to the WIF domain of Ryk/Drl – is poorly
understood, and many questions remain regarding this process. For example, current
evidence for binding of Wnts to Ryk/Drl is based mainly on co-immunoprecipitation or
the use of anti-Ryk/Drl postimmune sera. These studies do not preclude the possibility
that, rather than interacting directly with Wnt proteins, Ryk/Drl communicate indirectly
with Wnts through an intermediate factor. Even if the binding is direct, other proteins
may be necessary to form a functional signaling unit. Indeed, Ryk can be coimmunoprecipitated with both Wnt and Frizzled (Lu, Yamamoto et al. 2004), and sFRP2
(Secreted Frizzled-related Protein 2) blocks only Wnt3-Frizzled5 interactions but not
Wnt3-Ryk interactions (Schmitt, Shi et al. 2006), suggesting the possibility of a RykWnt-Frizzled ternary complex.
To begin addressing these questions, it is essential first to characterize the
interaction between Ryk/Drl and Wnt at a molecular level using tools from biophysical
and structural biology. In my efforts to understand the mammalian Ryk-Wnt system, I
encountered major experimental difficulties with obtaining well-behaved recombinant
Ryk and Wnt proteins. On the other hand, the Drosophila system has proven far more
tractable, since both Drl and DWnt5 could be readily obtained using insect cell
expression systems. Owing to the high sequence homology and functional similarity
between Drl and Ryk, understanding Drl-DWnt5 signaling should also shed light on the
molecular mechanism of their mammalian counterparts.
Using Drl-DWnt5 as a model system, my goals were to address the following
questions:
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1. Does Ryk/Drl interact directly with Wnt proteins? If so, what is the binding affinity?
2. Which protein region(s) is(are) responsible for the formation of Ryk/Drl-Wnt
complexes? Does the region of Wnt that binds Ryk/Drl overlap with the region that
binds Frizzleds – so that binding to the two classes of receptor would be mutually
exclusive – or do different regions of the Wnt surface bind to the different receptors?
In describing my studies, I start by describing the expression and purification of
individual proteins, followed by characterization of their binding using ‗pull-down‘ and
surface plasmon resonance (SPR) studies. I will then discuss structural insights into the
properties of the WIF domain from a Drl homolog that I have obtained using X-ray
crystallography. Based on this structure, I have generated and characterized a set of
mutations in the Drl WIF domain in order to locate the primary site for DWnt5 binding.
My studies serve as a good starting point for understand recognition of Wnt proteins by
the Ryk/Drl extracellular regions, and for interrogating Ryk/Drl signaling at a molecular
level.
2.2

Biophysical Characterization of Derailed-DWnt5 Interactions

2.2.1

Expression, Purification and Characterization of Drosophila Derailed and

DWnt5 Proteins
I was able to express the Drl extracellular region (residues 1 - 242) with a C-terminally
appended 6xHis tag in Sf9 cells at high levels. Purification of the secreted protein was
achieved as described in Experimental Procedures. Pure, glycosylated Drl full
extracellular region (sDrl) runs as a 35 kDa protein on SDS-PAGE gels (Figure 2.5A).
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Protein constructs with serial truncation from the C-terminus (up to residue 180) could be
expressed with similar yields and purified in the same way. Three N-linked glycosylation
sites (N63, N99 and N143) were identified within the Drl WIF domain. Mutating each of
these Asn residues independently to Gln causes disappearance of the upper (slower
mobility) band of sDrl in SDS-PAGE (Figure 2.5B), suggesting the presence of sugar
moieties at all three N-glycosylation sites.

Figure 2.5: Characterization of recombinant Derailed extracellular region. (A) SDS-PAGE of purified,
wildtype Drl full extracellular region (sDrl) with a C-terminally appended 6xHis tag. This gel was stained
with Coomassie Blue. (B) Western blot showing that point mutations at any of the predicted N-linked
glycosylation sites in the Drl extracellular region (N63, N99, or N143) resulted in faster protein migration
during SDS-PAGE, suggesting removal of glycan. sDrl proteins were detected using a pentahistidine
antibody that recognizes the 6xHis tag.
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DWnt5 contains an unusually long (~500 amino acids), non-conserved N-terminal
region (yellow in Figure 2.6A) as well as a ~150aa insert in the Wnt domain (blue in
Figure 2.6A) when compared with other Wnt proteins that consist primarily only of the
Wnt-homologous region (green in Figure 2.6A). In a Drosophila imaginal disc cell line,
DWnt5 protein is secreted in two forms – a full length, 140 kDa glycoprotein and a
proteolytic 80 kDa fragment (Fradkin, Noordermeer et al. 1995).
When full length DWnt5 is expressed in Drosophila Schneider 2 (S2) cells, it is
secreted mainly as a ~70 kDa glycoprotein (Figure 2.6B), similar in size to the reported
80 kDa proteolytic DWnt5 fragment (Fradkin, Noordermeer et al. 1995). The identity of
the DWnt5 protein was confirmed by Western blotting using two polyclonal antibodies
(kindly provided by Dr. Lee Fradkin (Fradkin, Noordermeer et al. 1995)). The epitope for
antibody A is located just N-terminal of the Wnt domain, whereas the epitope for
antibody B is located within the Wnt domain insert (Figure 2.6A).
Secreted, mature DWnt5 protein was extracted from the medium and purified as
described in the Experimental Procedures (Figure 2.6C). Surprisingly, the DWnt5
protein is stable in solution without detergents, a property that contrasts with that
described for other known Wnt proteins. The mature, ~70 kDa DWnt5 protein is the
result of proteolytic cleavage close to the C-terminus of the N-terminal region, as
suggested by the fact that it is recognized by antibody A (Figure 2.6B). N-terminal
protein sequencing at the Keck Facility (Yale University) showed that the major Nterminal starting sequence of mature DWnt5 protein is SQPSIS (residue 455 - 460). ESI
mass spectrometry of the purified protein (conducted by the CHOP Proteomics Core) also
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showed an absence of peptide coverage at N-terminal domain. Taken together, the mass
spectrometry and Western blotting results suggest that purified, mature DWnt5 protein
consists primarily of the Wnt domain, extending from residue 455 of DWnt5 to residue
1004 (although the C-terminus has not been confirmed).
To identify N-glycosylation sites within the mature DWnt5 protein, purified
DWnt5 protein was treated with PNGaseF in H2O18 and subjected to ESI mass
spectrometry (conducted by the CHOP Proteomics Core). Three N-glycosylation sites
were identified: N484-485 (KVSMENNTSVTD), N724 (NVDAKNDTSLV) and N952
(RVCHKNSSGLE). Indeed, PNGaseF-treated DWnt5 showed increased mobility in SDSPAGE, confirming the presence of surface-accessible N-linked glycosylation (Figure
2.6D). Surprisingly, mass spectrometry data readily identified peptide fragments
containing unmodified S868, the putative lipid modification site of DWnt5. This is an
unexpected result, which suggests that our recombinant DWnt5 protein is not lipid
modified at this site. The lack of lipid modification is consistent with the fact that our
DWnt5 protein has much better solubility characteristics than those seen for other Wnts.
The fact that we can generate quantities of purified DWnt5 useful for biochemical and
biophysical studies may open up unique opportunities for quantitative study of Wnt
signaling.
In order to examine whether the unique Wnt domain insert of DWnt5 (residue 681
to 838) is involved in Drl binding, a construct was generated in which the insert region of
DWnt5 was replaced with a short sequence (RERSFKRGSREQG) found in the equivalent
region of Wnt5 from the jumping ant Harpegnathos saltator, which has no such insert.
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The new, shortened construct is named DWnt5ΔB due to its lack of epitope for antibody
B. The mature form of purified DWnt5ΔB migrates more slowly in SDS-PAGE
compared to wildtype DWnt5 (Figure 2.6B left blot), possibly due to an alternative Nterminal cleavage site being used – or a different glycosylation pattern. Western blotting
of DWnt5ΔB confirmed the identity of the protein construct; it can be detected readily
using antibody against epitope A, but not with antibody against epitope B (Figure 2.6B
right blot), since this epitope has been removed.
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Figure 2.6: Characterization of DWnt5 protein. (A) Domain organization of DWnt5. Starting from the Nterminus: signal-peptide sequence (ss), N-terminal region (yellow), Wnt-homologous domain (green) and
Wnt domain insert (blue). The locations of two epitopes for DWnt5-specific rabbit polyclonal antibodies
are labeled A and B. (B) Western blots showing DWnt5 proteins secreted from S2 cells. DWnt5 was
detected by two different DWnt5 antibodies as indicated in (A). (C) SDS-PAGE gel of purified, mature
DWnt5 wildtype protein. (D) PNGaseF treatment of DWnt5 protein leads to increased mobility in SDSPAGE.
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2.2.2

Analysis of Derailed-DWnt5 Interactions by in vitro Pull-down and SPR

For an initial view of Derailed-DWnt5 interactions, we used a simple pull-down assay to
ask if the two recombinant proteins interact. Two C-terminally 6xHis tagged constructs
of purified recombinant Drl extracellular region (Drl residues 1-207 and Drl residues 1219) were used. Each sDrl protein was mixed with conditioned S2 medium containing
secreted DWnt5 protein. NiNTA beads were then added to the protein mixture to extract
sDrl proteins from the solution. The ability of sDrl proteins to pull down DWnt5 protein
from the medium was then examined by Western blotting with DWnt5 specific antibodies.
As shown in Figure 2.7, both sDrl proteins were able to extract DWnt5 from the solution,
as evidenced both by the loss of DWnt5 in the supernatant fraction and enrichment of
DWnt5 in the pull-down fraction. On the contrary, NiNTA beads did not effectively pull
down DWnt5 when the 6xHis-tagged sDrl protein was not included in the assay. These
results suggest that purified recombinant sDrl proteins interact with DWnt5 in vitro.
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Figure 2.7: Drl ectodomains are capable of pulling down DWnt5 from conditioned medium. S2 media
containing secreted DWnt5 protein (pre-concentrated by 10 fold) was mixed with NiNTA beads in the
presence (or absence) of purified Drl extracellular domains with an appended 6xHis tag. Two sDrl
constructs were used. One encompasses Drl residues 1-207 and the other encompasses Drl residues 1-219.
As controls, DWnt5-containing medium or the individual sDrl proteins were also mixed with NiNTA beads
on their own. Both sDrl proteins bound strongly to NiNTA beads whether DWnt5 was also present or not.
By contrast, DWnt5 was only enriched in the NiNTA pull-down fraction when added together with one of
the His-tagged sDrl proteins. NiNTA pull-down fractions were resuspend in 20% of the original media
volume, hence the stronger DWnt5 band intensity in the sDrl-free pull-down fraction compared to loading
control. A sample of S2 medium before pull-down experiment was analyzed as loading control.
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For more quantitative studies of direct interaction between purified sDrl and
DWnt5 proteins, we used surface plasmon resonance (SPR) with a Biacore 3000
instrument. Purified DWnt5 was immobilized onto a CM5 sensor chip using amine
coupling. Serial dilutions of sDrl proteins were then injected, and steady state binding to
the DWnt5-derivatized surface was recorded in SPR response units (RUs), corrected for
refractive index effects using a mock-derivatized control sensorchip surface. Steady state
RU values measured at different sDrl concentrations were then fit to a single-binding-site
hyperbolic curve (Figure 2.8A & B and Table 2.1). Wildtype, full sDrl (1-242) binds
directly to DWnt5 with a dissociation constant (KD) of 0.63 µM. Elimination of the Cterminal region of sDrl does not significantly affect the binding affinity; sDrl (1-180)
bound DWnt5 with a KD of 0.36 µM, suggesting that DWnt5 binding is mediated mostly
by the WIF domain, which ends at amino acid 161. The presence of sugar moieties at
N63 and N143 of sDrl also appears to have minimal influence on DWnt5 binding; sDrl 1180 with both of these glycosylation sites mutated to glutamine (N63Q/N143Q) also
bound DWnt5 with a very similar KD (0.54 µM).
To investigate whether the long insert region of DWnt5 contributes to Drl binding,
purified DWnt5ΔB protein was immobilized onto a CM5 sensorchip in the same way as
described for wildtype DWnt5, and its binding affinity for sDrl(1-242) was measured by
SPR (Figure 2.8C). The results show that DWnt5 wildtype and DWnt5ΔB proteins have
almost identical binding affinities for sDrl (Table 2.1). It is therefore clear that Drl
binding does not require the unique insert region of DWnt5.
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Figure 2.8: SPR studies of sDrl proteins binding to DWnt5 variants. (A) SPR studies with a series of
injections of the noted sDrl proteins onto a CM5 chip with immobilized wildtype DWnt5 protein. (B) A
representative SPR sensorgram of immobilized DWnt5 binding to sDrl(1-242) (at 320 nM concentration).
Colored squares represent actual data points. Sensorgram for DWnt5 immobilized CM5 chip surface is
colored red, and sensorgram for mock-derivatized control sensorchip surface is colored blue. Injection of
sDrl(1-242) protein solution starts at ~190 s and ends at ~430 s. (C) SPR studies in which a series of
injections of sDrl(1-242) at the indicated concentrations were applied to sensorchip surfaces containing
immobilized wildtype DWnt5 or DWnt5ΔB.

Table 2.1: SPR studies of different sDrl variants binding to DWnt5. Upper: sDrl constructs binding to
immobilized wildtype DWnt5. Lower: sDrl 1-242 binding to immobilized DWnt5ΔB.

Analyte

Binding KD (µM) to immobilized wildtype DWnt5

sDrl 1-242

0.63 ±0.08

sDrl 1-183

0.36 ±0.08

sDrl 1-180 N63Q&N143Q 0.54 ±0.05

Analyte

Binding KD (µM) to immobilized DWnt5ΔB

sDrl 1-242

0.75 ±0.11
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To investigate whether the two additional Drl homologues in D. melanogaster, Drl-2 and
Dnt, also bind DWnt5, SPR was used to assess the interactions of their extracellular
regions with purified DWnt5 (Figure 2.9A and Table 2.2). The full extracellular region
of Drl-2 (sDrl-2) displayed a very similar DWnt5-binding affinity to that of sDrl (KD =
0.15 µM). The Dnt extracellular region was also found to bind DWnt5, but with a
reduced affinity (KD = 2.5 µM), approximately four-fold lower than that for sDrl.
To demonstrate that immobilization of DWnt5 onto CM5 chip surface does not
significantly alter its binding properties in these studies, the reverse SPR experiments
were also performed, in which Drl homologs were immobilized onto the CM5 sensorchip
and purified free DWnt5 was injected (Figure 2.9B&C and Table 2.2). These studies gave
very similar results, with DWnt5 binding strongly to all three Drl homologs. KD values
for DWnt5 binding to immobilized sDrl, sDrl-2 and sDnt were 0.10 µM, 0.18 µM and
0.50 µM, respectively. Compared to the experiments performed with immobilized
DWnt5, these KD values are relatively lower (suggesting tighter binding), which can
likely be attributed to the fact that DWnt5 also weakly interacts with the negatively
charged dextran surface of the CM5 sensorchip (we have observed DWnt5 binding to
blank CM5 flow cell with high RUs at low micromolar concentrations).
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Figure 2.9: SPR studies of DWnt5 binding to D. melanogaster Drl homologs. (A) SPR studies used a CM5
sensorchip on which wildtype DWnt5 protein had been immobilized, and injections of the purified
extracellular domains of Drl homologs sDrl-2 and sDnt (at the indicated concentrations) were performed in
comparison to sDrl(1-242). (B) In a complementary experiment, SPR studies were performed with the
extracellular regions of the Drl homologs immobilized on the CM5 chip, and a series of injections of
wildtype DWnt5 protein at the indicated concentrations. (C) A representative SPR sensorgram of
immobilized sDrl binding to DWnt5 (at 160 nM concentration). Colored squares represent actual data
points. Sensorgram for sDrl immobilized CM5 chip surface is colored red, and sensorgram for mockderivatized control sensorchip surface is colored blue. Injection of DWnt5 protein solution starts at ~50 s
and ends at ~470 s. Injection of regeneration buffer starts at ~830 s and ends at ~980 s.

Table 2.2: SPR studies of Drl homologs binding to DWnt5. Upper table: Drl homologs binding to
immobilized DWnt5. Lower table: DWnt5 binding to immobilized Drl homologs.

Analyte

Binding KD (µM) to immobilized DWnt5

sDrl

0.63 ±0.08

sDrl-2

0.15 ±0.03

sDnt

2.4 ±0.2

Immobilized Drl homolog

Binding KD (µM) of wildtype DWnt5

sDrl

0.10 ±0.01

sDrl-2

0.18 ±0.02

sDnt

0.50 ±0.03
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2.3

Structure Determination of the Derailed-2 Extracellular Region

In an effort to gain a structural view of a Ryk/Drl family receptor extracellular region, a
great deal of time and effort was spent trying to crystallize sDrl, but without success.
However, crystals were obtained for the Drl-2 extracellular region, which has 44%
sequence identity to sDrl in the WIF domain region, and binds to DWnt5 with similar
affinity. The sDrl-2 crystals diffracted to 2.2 Å resolution on our home source X-ray
(Rigaku 007HF with Saturn CCD), and the structure was solved by molecular
replacement using a truncated poly-alanine model of the NMR structure of human WIF-1
as search model (Table 2.3).
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Table 2.3: Derailed-2 extracellular domain crystallographic statistics (molecular
replacement)
Drl-2 ectodomain
Data collection

Rigaku 007HF

Space group

C2221

Cell dimensions
a, b, c (Å)

56.954 91.615 76.379

Resolution (Å)

50.00 - 2.25 (2.29-2.25) *

Rsym or Rmerge

0.054 (0.327)

I / σI

42.5 (4.4)

Completeness (%)

99.3 (94.3)

Redundancy

6.5 (3.5)

Refinement
Resolution (Å)

50.00 – 2.25

No. reflections

8664

Rwork / Rfree

22.0/26.4

Model
Protein amino acids

aa 26-178

No. atoms

1292

Protein

1209

Sugar

42

Water

41

R.m.s. deviations
Bond lengths (Å)

0.016

Bond angles (º)

2.148

*Values in parentheses are for highest-resolution shell.
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Similar to hWIF-1, the Drl-2 WIF domain consists of two α helices and nine β
strands (Figure 2.10A), with overall Cα root mean squared deviation (RMSD) of 2.0 Å
between these two WIF domains using SSM superimposition (Krissinel and Henrick
2004). The N-terminal residue Y26 (immediately after the predicted cleavage site for the
signal peptide) forms the start of strand β1, and the C-terminal tail is located on the
opposite side of the domain. Two cysteines, C125 and C160, form a conserved disulfide
bond near the C-terminus that links strands 7 and 9. Clear electron density was
observed for sugar moieties at two N-linked glycosylation sites (N128 and N148), and
one O-linked glycosylation site (S171).
Figure 2.10B shows an overlay of the sDrl-2 WIF domain (cyan) with the hWIF-1
NMR structure (no lipid bound, red) (Liepinsh, Banyai et al. 2006) and hWIF-1 domain
crystal structure (lipid bound, yellow) (Malinauskas, Aricescu et al. 2011) using PyMOL
to minimize RMSD of all matched atoms. The most significant structural difference lies
in the conformations and positions of the two helices, 1 and 2. For hWIF-1, a
comparison between the lipid-free NMR structure and the lipid-bound crystal structure
suggests that binding of phospholipid causes an inward shift of helix α1 relative to that in
the solution NMR structure, whereas the helix α2 region appear to stretch outwardly to
accommodate the phospholipid. Unlike hWIF-1, there is no electron density – or space –
for an embedded phospholipid in our crystal structure of the sDrl-2 WIF domain.
Nevertheless, the position of helix α1 resembles that seen in the phospholipid-bound
hWIF-1 structure rather than in the lipid-free NMR structure. On the other hand, the helix
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α2 region of the sDrl-2 WIF domain most closely matches that seen in the lipid-free
hWIF-1 NMR structure, despite the fact that this region of sDrl-2 (as well as Ryk/Drl/Dnt)
is six residues shorter than that in hWIF-1. It is also worth noting that the region
encompassing α2 and β3 of hWIF-1 appears to be the most flexible part of the NMR
structure (Liepinsh, Banyai et al. 2006), suggesting that this flexibility is required for
allowing access of the bound phospholipid. Interestingly, preliminary molecular
dynamics (MD) simulations of Drl-2 WIF domain suggest similar flexibility in this
region.
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Figure 2.10: Crystal structure of sDrl-2 extracellular domain. (A) Overall crystal structure of sDrl-2. (B)
Overlay of sDrl-2 WIF domain with hWIF-1 structures. Cyan: crystal structure of sDrl-2 WIF domain, with
two helices labeled. Red: NMR structure of hWIF-1 (no lipid bound, PDB 2D3J). Yellow: crystal structure
of hWIF-1 (phospholipid bound, PDB 2YGN). Phospholipid is shown in yellow sticks.
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In the sDrl-2 crystal structure, a crystallographic dimer is formed that involves
intimate symmetrical interactions between the surface encompassing helices α1 and α2 of
one molecule and the same region on its symmetry mate (Figure 2.11A). The binding
interface is highly hydrophobic, formed by V36, M37, M40, G41, L42, A44 and L46
around helix α1, together with Y57, A58, F61, T62, P64 and P66 from α2-β3 region, with
additional polar interactions involving the Q132 and N157 at the periphery of the
interface. The buried surface area is ~ 300 Å2 on each molecule, with a shape
complementarity of 0.76. Given the high shape complementarity and the fact that most of
these residues are conserved across Ryk family RTKs (Figure 2.4B), it is possible that
this interface drives homodimer formation during Ryk/Drl signaling. On the other hand,
since the same region on the surface of hWIF-1 is postulated to bind the acyl chain of
Wnt proteins, another intriguing possibility is that this conserved region on Ryk/Drl is
responsible for Wnt ligand binding – which will be mutually exclusive with this mode of
dimerization.
In the crystal, the Ala/Pro-rich C-terminal tail of sDrl-2 lies across the ‗back‘
surface of another symmetry mate (Figure 2.11B). It is unclear whether this interaction
has any physiological relevance for sDrl-2 to carry out its function, or is simply caused
by crystal packing. A similar sequence is not present in other members of the Ryk/Drl
family. The seven-residue linker region between the WIF domain and Ala/Pro-rich C-tail
(residue 164-170) of sDrl-2 is too short to allow the tail to fold back onto its own WIF
domain.
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Figure 2.11: Crystal packing of sDrl-2. (A) Packing at the symmetrical interface of the crystallographic
dimer involving the 1/2 region. (B) Packing of the sDrl-2 C-terminal tail against the WIF domain of
another symmetry mate.
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2.4

Structure-Guided Point Mutations in the Derailed Extracellular Region

Disrupt its Binding to DWnt5
Due to the high sequence similarity between the sDrl and sDrl-2 WIF domains (44%
identical), most of the features observed in the sDrl-2 crystal structure are very likely also
to be present in sDrl. Using the sDrl-2 structure as a template, I built a homology model
of the sDrl WIF domain using the SWISS-MODEL server (Figure 2.12) (Arnold, Bordoli
et al. 2006). The model has a QMEAN4 global score of 0.661 and a Z-score of -1.45,
indicating a high level of confidence in model reconstruction (Benkert, Biasini et al.). A
surface conservation analysis was then conducted on the structural model of the sDrl WIF
domain, using ClustalW sequence alignment of Drl sequences from eight invertebrate
species as template (Figure 2.12A, see Experimental Procedures for details). Surface
residues in the structural model are colored based upon their conservation in the
alignment: red colored regions indicate high conservation, whereas white colored regions
indicate low conservation. The three N-glycosylation sites are colored green. Among all
surface exposed areas, the surface shown in the lower right part of Figure 2.12A stands
out as the most conserved area within the Drl WIF domain (and it is not blocked by Nlinked glycosylation sites). A closer look (Figure 2.12B) at this surface area identifies the
conserved residues involved, which can be divided into three regions: E40, L41, Y42,
K45 and E46 around strand β2 (region 1, colored green); I49, N50, Y52, A53, N55, F56,
V58, P59 and P61 on the helix α2/strand β3 segment (region 2, colored orange); E126,
K152 and I154 form the third region (region 3, colored yellow). These residues are also
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among the most conserved residues between WIF domains of Drl homologs (Figure
2.4B).
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Figure 2.12: Surface conservation of Drl WIF domain homology model. (A) Illustration of surface
conservation of the Drl WIF domain. The most conserved residues are colored red and the least conserved
residues are colored white. The three N-glycosylation sites are colored green. (B) Stick and ribbon
representation of the conserved residues in the structural model of Drl WIF domain. The model orientation
is the same as the lower right figure in (A).

As mentioned in the previous section, the rather hydrophobic region around
helices 1 and 2 forms the interface of a crystallographic homodimer in our crystal
structure of sDrl-2. High evolutionary conservation also suggests that it may be
responsible for binding to Wnt proteins. To test the latter possibility, point mutations
were introduced into each area of sDrl, and the resulting variants were tested for their
ability to bind DWnt5 using SPR assays (Figure 2.13 and Table 2.4). Any mutation in
region 2 (Y52E, F56E and V58E: orange) – in the α2/β3 segment – abolished binding of
sDrl to DWnt5. An E40K mutation in region 1 (green) also decreased binding affinity to
DWnt5 by ~10 fold. The other two mutations in region 1, L41E and Y42E, caused
aggregation of sDrl during gel filtration, so their effects on DWnt5 binding could not be
characterized. By contrast with these examples, mutations in region 3 of sDrl (E126K and
I154E: yellow) had no effect on DWnt5 binding affinity. Therefore, the segment
encompassing helices α2 and strand β3 (region 2) on sDrl appears to be responsible for
DWnt5 binding, with hydrophobic residues in the segment (Y52, F56, V58) being
implicated. E40 in Region 1 (at the beginning of strand 2) may also contribute to
DWnt5 binding.
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Figure 2.13: SPR studies to characterize the effect of point mutations in sDrl (1-242) on binding to
immobilized DWnt5 wildtype protein.
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Table 2.4: SPR studies of DWnt5 binding property of Drl ectodomain proteins (residue 1-242) with single
point mutation.

Analyte

Binding KD (µM) to immobilized DWnt5

sDrl wildtype

0.63 ±0.09

sDrl E40K

6.1 ±0.3

sDrl L41E

Aggregation in solution

sDrl Y42E

Aggregation in solution

sDrl Y52E

47 ±13

sDrl F56E

99 ±142

sDrl V58E

69 ±19

sDrl E126K

0.67 ±0.07

sDrl I154E

0.62 ±0.08
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2.5

Summary and Discussion of Derailed-DWnt5 Studies

In this study, I have characterized the interaction between Derailed family receptor
tyrosine kinases and its ligand, DWnt5, in vitro using purified proteins. I have shown, for
the first time, that Ryk/Drl family proteins‘ extracellular region binds directly to a Wnt
ligand. The DWnt5 binding affinities (KD) of Drl homologs lie in the range of 100 nM to
low micromolar as determined by SPR. A crystal structure of sDrl-2 has revealed
important features of the WIF domains of Drl family proteins. Based on the structure, the
region on the Drl WIF domain that is responsible for DWnt5 binding has been mapped
using site-directed mutagenesis and SPR assays. The residues implicated form a ring
around a depression that lies between the two -helical regions, suggesting that this is the
key ligand-binding site.
Given the high sequence homology within the mammalian and Drosophila
Ryk/Drl family and Wnt family, the interaction mode and binding interface of DrlDWnt5 characterized here are likely to be conserved in the case of human Ryk-Wnt
interactions. Unfortunately, due to experimental difficulties in generating useful
quantities of the soluble Ryk extracellular region and human Wnt proteins in detergentfree conditions, similar biophysical studies have not proven possible using this strategy.
Previous studies in the literature have attempted to measure the interaction
affinities between Wnt proteins and their cell surface receptors such as Frizzled, Ror and
Ryk using cell-based or ELISA assays. Most of those studies have reported KD values in
the low nanomolar range. For example, Liu et al. (Liu, Shi et al. 2005) reported a KD
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value of 8 nM for binding of human Wnt1 to cell surface-expressed Ryk. Using a similar
cell-based overlay assay and a Wnt3/alkaline phosphatase fusion protein, Schmitt et al.
(Schmitt, Shi et al. 2006) also measured Wnt3 – Ryk interaction with an apparent KD
value of 4 nM. These reported values are more than an order of magnitude lower
(suggesting tighter binding) than that of the Drl-DWnt5 interaction which I have
determined in SPR assays. This is a common observation in studies of cell surface
receptors. For example, although cellular studies of EGF binding to its receptor yield KD
values in the low nanomolar (6-12 nM) range (Burgess, Cho et al. 2003), studies of EGF
binding to the isolated extracellular region of its receptor typically yield well-validated
KD values in the 100-200 nM range (Dawson, Berger et al. 2005) – revealing a similar
difference of an order of magnitude as seen in my DWnt5 studies. These differences can
arise for several reasons, and are not likely to reflect any intrinsic difference between the
binding properties of Drl and DWnt5 when compared with other receptor/Wnt complexes.
If Wnt binding induces receptor dimerization, this dimerization will be favored in the
membrane context compared with solution – and the resulting linked equilibria will yield
a higher apparent Wnt binding affinity for cellular assays. The differences might also
reflect the different assay systems employed. For example, the detection antibodies
employed in the cell-based or ELISA-based studies (for measuring the amount of bound
protein) frequently cause self-association of both receptor and ligand, which will at the
same time increase the avidity (and therefore apparent affinity) of binding. Alternatively,
the differences might reflect the presence of other cellular factors that contribute to
complex formation. Extracellular ligands such as Wnt proteins commonly display weak
interactions with the sugars, proteoglycans, and (since they are acylated) hydrophobic
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membranes present on the surface of cells. Interactions of this sort would contribute to
the increased binding affinity observed in cellular studies. In addition, the presence of a
co-receptor cannot be ruled out.
It is intriguing to postulate what might happen after binding of Wnt to Ryk/Drl on
the cell surface. Ryk/Drl contain an intracellular pseudokinase domain that has no
observable kinase activity, even when they are clustered (and oligomerized) onto lipid
vesicles (my unpublished results). If the intracellular domains of Ryk/Drl have no
catalytic function, they must initiate downstream signaling through as-yet-unknown
signaling mechanism, which (in the absence of kinase activity) sets them apart from other
RTKs. Unlike seven transmembrane domain proteins such as like GPCRs, the
cytoplasmic region of Ryk/Drl is linked to extracellular Wnt binding through a single
transmembrane domain, making it unlikely that a ligand-induced conformational change
could be propagated across the membrane without either ligand-induced dimerization or
association (heterodimerization) with some other cell-surface molecules – which could be
other Wnt receptors, for example.
Several studies have already suggested that Wnt ligands can bind simultaneously to
Ryk and other cell surface receptors. For example, a Ryk/Wnt/Frizzled complex can be
co-immunoprecipitated (Lu, Yamamoto et al. 2004), indicating the formation of ternary
complex. In addition, the soluble Ryk extracellular region blocks Wnt binding to cellsurface Ryk, but not to Frizzleds – whereas secreted Frizzled-like proteins block Wnt
binding to cell-surface Frizzled but not to Ryk (Schmitt, Shi et al. 2006). Thus, the basis
for Wnt binding to these classes of receptor appears to be different, suggesting different
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Wnt recognition properties for the WIF and CRD domains. Ryk has also been shown to
co-immunoprecipitate with receptors EphB2 and EphB3 (Halford, Armes et al. 2000;
Trivier and Ganesan 2002; Kamitori, Tanaka et al. 2005). Taken together, these data
suggest that Wnt binding may brings Ryk/Drl into close proximity with other cell
receptors, with which it collaborates in promoting intracellular signaling.
Many important questions remain to be addressed concerning the Ryk/Drl-Wnt
signaling system. For the next steps of this study, key goals will include the following:
1. Structural characterization of Wnt proteins using X-ray crystallography and
hydrogen/deuterium (H/D) exchange, and identification of the region(s)
responsible for binding to Ryk/Drl.
2. Addressing the cellular signaling effects of Ryk/Drl-Wnt when binding-defective
mutations are introduced.
3. Determining the stoichiometry of the Ryk/Drl-Wnt complex, and assessing
whether DWnt5 binding induces dimerization of Ryk/Drl extracellular regions.
4. Understanding the signaling mechanisms of Wnt-bound Drl/Ryk.
At present, the only structural information of Wnt family protein comes from the
crystal structural of XWnt8 in complex with a mouse Frizzled-8 CRD domain with which
it was co-expressed; this co-expression was required for production of soluble XWnt8.
Unlike other Wnts, DWnt5 can be purified in large quantities and is well-behaved in
solution without detergents – making it a promising candidate for crystallographic studies
to provide further structural information of Wnt proteins. In particular, since the only
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Wnt structure known is bound to a Frizzled CRD, it will be important to determine a
structure of a free Wnt protein. Additionally, a co-crystal structure of DWnt5 with sDrl
(or other sDrl homologs) will greatly help our understanding of their binding mode.
Alternatively, in the absence of a DWnt5 crystal structure, H/D exchange method coupled
with mass spectrometry can offer important structural insights regarding the structural
dynamics of Wnt domain and also likely identify DWnt5 segments that are responsible
for Drl binding when it is performed with DWnt5-Drl complex.
Albeit soluble, mature wildtype DWnt5 protein has heterogeneous N-terminal start
sites as well as a long, 150 amino acids insert in the Wnt domain. These properties
introduce potential structural heterogeneity and instability for further biophysical
characterization, especially protein crystallography. Several strategies are being
employed in order to improve current DWnt5 protein construct for crystallography
purposes:
1. Replacing the long Wnt domain insert with a short 6xHis tag, which serves two
purposes: (a) removing the loop to improve protein homogeneity and stability,
and (b) allowing an additional purification step using NiNTA resin. Removal of
this region should have minimal effect on Wnt domain integrity since (a) most of
Wnt5 homologs found in other species do not have such an insert and (b) the
DWnt5ΔB construct fully retains sDrl binding affinity and has better expression.
2. Introducing a TEV protease cleavage site in between residue 470-540 to remove
the extra N-terminal non-conserved residues and to improve protein homogeneity.
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This region is in between the poly-serine segment (and N-terminal start of mature
DWnt5) 455-SQPSISSSSSS-465 and the Wnt domain.
With completion of the goals summarized above, the insights I have gained into Wnt
signaling through Drl proteins will be further developed towards a mechanistic
understanding of this important signaling axis.
2.6

Experimental Procedures for Chapter 2

Expression and Purification of sDrl and DWnt5 Proteins
For sDrl expression, DNA encoding 6xHis tagged Drl full extracellular region (1-242)
was cloned into pFastBac1 using 5‘-GAATGGATCCAACATGGCCCCCAACTTGCTAACAA
TCGGATTAC-3‘ as forward primer and 5‘-GAATCTCGAGTTAGTGATGGTGATGGTGATG
GCCACTGGCCGGTGGCACCAG-3‘ as reverse primer. Recombinant baculoviruses were
generated using the Bac-to-Bac system (Invitrogen). For protein expression, Sf9 medium
was harvested three days post infection and subjected to extensive dialysis at 4 ˚C.
Proteins were then extracted from medium using self-packed NiNTA resin. NiNTA resin
was washed twice with low imidazole buffer (20 mM HEPES pH 7.5, 150 mM NaCl and
15 mM imidazole) and sDrl protein was then eluted from NiNTA resin with buffer
containing 20 mM HEPES pH 7.5, 150 mM NaCl and 100 mM imidazole. sDrl protein
was further purified using an UnoQ anion exchange column (BioRad) (loading buffer
was 20 mM HEPES pH7.5 and 70 mM NaCl, with an elution gradient of 70 mM -1 M
NaCl) and a Superose 12 sizing column (GE Healthcare) (running buffer: 10mM HEPES
pH 7.5 and 150mM NaCl), with a final yield of ~ 1mg/liter of medium. All purifications
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were performed at room temperature. Other sDrl variants are purified in the same way.
pFastBac1 plasmids containing either sDrl-2 or sDnt were obtained from Dr. Lee Fradkin.
Both constructs contain ORF encoding full extracellular regions of either Drl-2 or Dnt
with native signal peptide and a C-terminal RPLESRGPFEGKPIPNPLLGLDSTR
TGHHHHHH sequence.
For expression of DWnt5 protein, S2 cells were stably transfected with a mixture
of three plasmids (i) pUAST-DWnt5, (ii) pAc-Gal4 and (iii) pCoHygro (10g:10g:1g)
using calcium phosphate method, and were selected in Schneider‘s medium (Sigma)
supplemented with 10% fetal calf serum (Sigma, Cat#F0643) and 300 g/ml hygromycin
(cellgro) for 3 weeks. Schneider‘s cell medium was then replaced with EXCELL 420
serum-free medium (SAFC Biosciences) for subsequent cell culture, and constitutive
secretion of DWnt5 into the medium was verified using DWnt5 specific antibodies
(Fradkin, Noordermeer et al. 1995). Binding of Gal4 protein (constitutively expressed
from pAc-Gal4 vector) to the promoter region of pUAST-DWnt5 induces high-level
expression of DWnt5 protein in S2 cells. For large scale DWnt5 expression, cells were
seeded at 4x106 cells/ml in spinner flasks. After 5 days of growth, medium (~3 litres) was
harvested and flowed through 4ml Fractogel SO3 (EMD) resin at 4˚C. Then SO3 resin
was washed twice with 10ml of wash buffer (20 mM HEPES pH 7.5, 250 mM NaCl).
DWnt5 was then eluted from SO3 column with three washes of 4ml elution buffer (20
mM HEPES pH 7.5, 900 mM NaCl). Protein solution was then diluted with 3 volumes of
20 mM HEPES pH7.5 buffer to lower the NaCl concentration to <250 mM. All
subsequent purification steps were performed at room temperature. The protein sample
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was next loaded onto a self-packed 2ml Fractogel SO3 FPLC column pre-equilibrated
with 20 mM HEPES pH7.5 and 150 mM NaCl. A gradient from 150 mM – 1 M NaCl
was then used to elute the bound DWnt5 protein from the column (elution peak around
650mM NaCl). Eluted fractions were then diluted again with 3 volumes of 20 mM
HEPES pH7.5 buffer, loaded onto CHT2 column (BioRad) equilibrated with buffer
containing 20 mM HEPES pH7.5, 150 mM NaCl, 2.5 mM NaH2PO4, 2.5 mM K2HPO4.
A 0-100% gradient of Buffer B (250 mM NaH2PO4, 250 mM K2HPO4 and 150 mM NaCl)
was used to elute the protein. Finally, eluted fractions were pooled together, concentrated,
and loaded onto a Superose 6 column (GE Healthcare) with running buffer containing 10
mM HEPES pH 7.5 and 150 mM NaCl. The purified protein could be flash frozen in the
presence of 10% glycerol with no significant aggregation or loss of sDrl-binding activity
upon thawing.
Pull-down of DWnt5 by Drl Extracellular Regions
EXCELL 420 serum-free S2 medium containing secreted DWnt5 was concentrated by
10-fold in an Amicon concentrator. The purified recombinant Drl extracellular region
(sDrl) was added at a 1 µM final concentration to 1.2 ml of concentrated S2 medium, and
incubated for 2 hours at 4 ˚C. Then, 60 µl of pre-washed NiNTA bead slurry (enough to
bind all the added 6xHis-tagged sDrl) was added to the solution for an additional hour at
4 ˚C. Supernatant and beads were then separated and NiNTA beads were resuspended in
buffers (20 mM HEPES pH7.5, 150 mM NaCl) to make samples for Western blotting
using rabbit anti-DWnt5 polyclonal Ab (epitope B, (Fradkin, Noordermeer et al. 1995))
and mouse anti-His5 Ab (QIAGEN).
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Surface Plasmon Resonance Studies
SPR experiments were performed using a Biacore3000 instrument (GE). DWnt5 protein
was immobilized onto a CM5 sensorchip using the amine coupling method as
recommended by the manufacturers. Briefly, purified DWnt5 protein was diluted in
HBS-EP buffer (10 mM HEPES pH7.5, 150 mM NaCl, 3 mM EDTA, 0.005%
Polysorbate 20) to a final concentration of 1 µM and allowed to flow across an
EDC/NHS-activated CM5 chip surface at 5 µl/min for a total volume of 100 µl. The
sensorchip surface was then quenched with an injection of 1M ethanolamine pH 8.0.
Typically, about 10000 RU of DWnt5 was immobilized onto the surface. DWnt5
sensorchips were relatively stable in a short term (1-2 weeks), as determined by tests of
sDrl binding, when stored at 4 °C, but tended to lose sDrl binding affinity and capacity
(in terms of both KD and Bmax) over time.
For sDrl binding experiments, 10 samples of purified, serially diluted (1:1 in
HBS-EP) sDrl proteins (20 µM - 4 nM) were prepared. Then samples were sequentially
injected at room temperature, starting from the lowest concentration. For each injection,
steady state binding of protein was achieved, and bound sDrl proteins were then allowed
to spontaneously detach from the sensorchip surface after each injection in HBSEP
running buffer. An example sensorgram, including the dissociation phase, is shown in
Figure 2.8B. In a typical case, the SPR signal fell to with 20 RUs of that measured
before ligand injection by the end of the dissociation phase (typically 5 minutes). RUs
recorded from steady state binding at each concentration were then used to fit the sDrl
binding curve to a simple hyperbola using Prism software.
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For the reverse experiment (immobilizing sDrl homologs and flowing DWnt5
protein across the Drl-derivatized surfaces), 25 µM of purified extracellular regions of
Drl homologs (in 8 mM HEPES pH 7.5, 120 mM NaCl, 10% glycerol) were diluted 1:4
in 10mM sodium acetate (pH 4.5) solution and flowed across an activated CM5
sensorchip surface at 10µl/min for 9 minutes. About 10000 - 14000 RUs of each Drl
homolog were immobilized onto the surface. Purified DWnt5 protein was then injected
on to the sensor chip (concentrations from 10 nM to 5 µM), and was allowed at each
injection to reach steady state binding (typically 10µl/min for 7 minutes). A typical
sensorgram is shown in Figure 2.9C. 25µl of regeneration buffer (10 mM sodium acetate
pH4.5 and 500 mM NaCl) was then used to wash off bound DWnt5 proteins from the
CM5 surface after each injection, bringing the SPR signal after each experiment down to
within 10% of the maximal binding RU of that injection. Other aspects of the
experimental setup are similar.
Crystallography and Structural Determination of sDrl-2
sDrl-2 full extracellular region (1-183) with a C-terminal Factor Xa (FXa) cleavage site
(IEGR), spacer peptide (ASGPFEGKPIPNPLLGLDSTRTG) and 6xHis tag was subcloned
into pFastBac1 vector and expressed in Trichoplusia ni cells using baculovirus infection
and ESF921 medium (ExpressionSystems). Cell-conditioned medium was collected and
passed through a NiNTA column. The column was then washed twice with low imidazole
buffer (20 mM HEPES pH 7.5, 150 mM NaCl and 15 mM imidazole) and sDrl2 protein
was eluted from NiNTA bead with buffer containing 20 mM HEPES pH 7.5, 150 mM
NaCl and 100 mM imidazole. After buffer exchange to remove imidazole, FXa protease
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was used to cleave the 6xHis tag from the protein (10 µg protease for 1 mg purified sDrl2 in 1 ml solution for 1 hour at room temperature). Cleaved sDrl-2 protein was then
passed through a Superose 12 sizing column (GE Healthcare) equilibrated with gel
filtration buffer (10 mM HEPES pH 7.5, 150 mM NaCl) at room temperature. Protein at
the major peak was collected, partially deglycosylated with PNGaseF (New England
BioLabs) (2,000 Unit/mg of sDrl-2 protein) for 3 hours at room temp and concentrated to >
12 mg/ml for crystallization. Crystals were grown at 21˚C using the hanging drop vapor
diffusion method by mixing 1 µl protein solution with 1 µl well solution containing 100
mM Tris pH 8.5, 25% PEG 6000, 100 mM Sodium Acetate and 15% glycerol. Crystals
formed within 2 days and were frozen directly in liquid nitrogen. Data were collected
using a home source X-ray unit (Rigaku), and were processed using HKL2000 software
(Otwinowski and Minor 1997). Initial phasing was obtained by molecular replacement
using a truncated poly-alanine model of the NMR structure of human WIF-1(PDB: 2D3J)
(Liepinsh, Banyai et al. 2006) as the search model in Phaser (CCP4 (Collaborative
Computational Project Number 4) 1994). Structural refinement and model building were
carried out using Refmac (CCP4 (Collaborative Computational Project Number 4) 1994)
and Coot (Emsley and Cowtan 2004). Structure figures were generated using PyMol
(DeLano 2002).
Homology Modeling and Surface Conservation Analysis of Drl WIF Domain
Homology model of Drl WIF domain was built using the SWISS-MODEL server (Arnold,
Bordoli et al. 2006) based on the crystal structure of sDrl-2 ectodomain. Surface
conservation analysis was conducted based on alignment of Drl protein sequences from
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eight invertebrate species: GI17137162 (Drosophila melanogaster), GI194759318
(Drosophila ananassae), GI195049987 (Drosophila grimshawi), GI195115220
(Drosophila mojavensis), GI157130072 (Aedes aegypti), GI91092648 (Tribolium
castaneum), GI328789866 (Apis mellifera) and GI156547777 (Nasonia vitripennis).
Illustration of surface conservation was generated using UCSF Chimera software
(Pettersen, Goddard et al. 2004).
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Appendix 1

List of Kinase Inhibitors Used in Chapter 1.2.3

(Calbiochem Cat. # 539744)
ID

Plate
Location

Catalog
Number

1
2
3
4
5

A1
A2
A3
A4
A5

DMSO
121767
121790
124011
124012

6

A6

124018

7

A7

124020

8

A8

9
10
11

Product Description

CAS
Number

PubChem
Compound
ID#

AG 1024
AGL 2043
Akt Inhibitor IV
Akt Inhibitor V, Triciribine

65678-07-1
226717-28-8
681281-88-9
35943-35-2

2044
9817165
5719375
290486

Akt Inhibitor VIII, IsozymeSelective, Akti-1/2
Akt Inhibitor X

612847-09-3

10196499

925681-41-0

16760284

521275

PDK1/Akt/Flt Dual Pathway
Inhibitor

5113385

A9
A10
A11

189404
197221
203290

Aurora Kinase Inhibitor II
Bcr-abl Inhibitor
Bisindolylmaleimide I

331253-86-2
and
329710-24-9
331770-21-9
778270-11-4
133052-90-1

12
13
14
15
16
17

A12
B1
B2
B3
B4
B5

BLANK
DMSO
203297
203696
220285
234505

Bisindolylmaleimide IV
BPIQ-I
Chelerythrine Chloride
Compound 56

119139-23-0
174709-30-9
3895-92-9
171745-13-4

2399
2427
72311
2857

18
19
20
21

B6
B7
B8
B9

260961
260962
528100
266788

154447-35-5
404009-40-1
371935-74-9
120166-69-0

9860529
9859309
9884685
657356

22
23
24
25

B10
B11
B12
C1

317200
324673
BLANK
DMSO

DNA-PK Inhibitor II
DNA-PK Inhibitor III
PI-103
Diacylglycerol Kinase
Inhibitor II
DMBI
EGFR/ErbB-2 Inhibitor

5812-07-7
179248-61-4

5353593
9843206

26
27

C2
C3

324674
324840

879127-07-8
881001-19-0

9549299
11566580

28
29
30

C4
C5
C6

343020
343021
344036

EGFR Inhibitor
EGFR/ErbB-2/ErbB-4
Inhibitor
Flt-3 Inhibitor
Flt-3 Inhibitor II
cFMS Receptor Tyrosine

301305-73-7
896138-40-2
870483-87-7

1048845
11601743
11617559

123

6610278
5311510
2396

31
32

C7
C8

365250
365251

33
34

C9
C10

371806
375670

35
36
37
38
39
40

C11
C12
D1
D2
D3
D4

343022
BLANK
DMSO
407248
407601
420099

41
42
43
44
45
46

D5
D6
D7
D8
D9
D10

47
48
49
50
51
52

Kinase Inhibitor
Gö 6976
Gö 6983

136194-77-9
133053-19-7

3501
3499

GTP-14564
Herbimycin A,
Streptomyces sp.
Flt-3 Inhibitor III

34823-86-4
70563-58-5

3385203
16760502

852045-46-6

11772958

IGF-1R Inhibitor II
IRAK-1/4 Inhibitor
JAK Inhibitor I

196868-63-0
509093-47-4
457081-03-7

9549305
11983295
5494425

420104
420121
420126
428205
440202
440203

JAK3 Inhibitor II
JAK3 Inhibitor IV
JAK3 Inhibitor VI
Lck Inhibitor
LY 294002
LY 303511

211555-04-3
58753-54-1
856436-16-3
213743-31-8
154447-36-6
154447-38-8

3795
176406
16760524
6603792
3973
3971

D11
D12
E1
E2
E3
E4

448101
BLANK
DMSO
513035
513040
521231

Met Kinase Inhibitor

658084-23-2

9549297

171179-06-9
216163-53-0
249762-74-1

4707
4709
5330548

53

E5

521232

205254-94-0

10907042

54

E6

521233

627518-40-5

9797370

55
56
57

E7
E8
E9

521234
527450
527455

347155-76-4
608512-97-6
852547-30-9

16760609
6490494
16760619

58
59
60

E10
E11
E12

528106
528108
BLANK

PD 158780
PD 174265
PDGF Receptor Tyrosine
Kinase Inhibitor II
PDGF Receptor Tyrosine
Kinase Inhibitor III
PDGF Receptor Tyrosine
Kinase Inhibitor IV
PDGF RTK Inhibitor
PKR Inhibitor
PKR Inhibitor, Negative
Control
PI 3-Kg Inhibitor
PI 3-KbInhibitor II

648450-29-7
648449-76-7

5289247
5287855

61
62
63
64
65
66

F1
F2
F3
F4
F5
F6

DMSO
529574
529581
539652
539654
553210

PP3
PP1 Analog II, 1NM-PP1
PKCbII/EGFR Inhibitor
PKCb Inhibitor
Rapamycin

5334-30-5
221244-14-0
145915-60-2
257879-35-9
53123-88-9

4879
5154691
6711154
6419755
16760631

67

F7

555553

Rho Kinase Inhibitor III,
Rockout

7272-84-6
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644354

68
69
70

F8
F9
F10

555554
539648
567805

Rho Kinase Inhibitor IV
Staurosporine, N-benzoylSrc Kinase Inhibitor I

not registered
120685-11-2
179248-59-0

16760635
16760627
1474853

71
72
73
74
75
76

F11
F12
G1
G2
G3
G4

572660
BLANK
DMSO
574711
574712
574713

SU11652

326914-10-7

5329103

Syk Inhibitor
Syk Inhibitor II
Syk Inhibitor III

622387-85-3
227449-73-2
1485-00-3

6419747
16760670
672296

77
78
79
80
81
82

G5
G6
G7
G8
G9
G10

616451
616453
658390
658401
658440
658550

TGF-b RI Kinase Inhibitor
TGF-b RI Inhibitor III
AG 9
AG 490
AG 112
AG 1295

396129-53-6
356559-13-2
2826-26-8
133550-30-8
144978-82-5
71897-07-9

447966
16079009
2063
5328779
5328804
2048

83
84
85
86
87

G11
G12
H1
H2
H3

658551
BLANK
DMSO
658552
676480

AG 1296

146535-11-7

2049

175178-82-2
15966-93-5

2051
6419834

88

H4

676481

269390-69-4

9797919

89

H5

676482

286370-15-8

9549295

90

H6

676485

288144-20-7

5329155

91

H7

676487

204005-46-9

5329098

92

H8

676489

216661-57-3

5329468

93
94

H9
H10

260964
189405

AG 1478
VEGF Receptor 2 Kinase
Inhibitor I
VEGF Receptor Tyrosine
Kinase Inhibitor II
VEGF Receptor Tyrosine
Kinase Inhibitor III, KRN633
VEGF Receptor 2 Kinase
Inhibitor II
VEGF Receptor 2 Kinase
Inhibitor III
VEGF Receptor 2 Kinase
Inhibitor IV
DNA-PK Inhibitor V
Aurora Kinase Inhibitor III

404009-46-7
879127-16-9

16760391
9549303

95

H11

569397

Staurosporine,
Streptomyces sp.

62996-74-1

451705

96

H12

BLANK
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Appendix 2

A Chemical Genetic Approach to Study ErbB Signaling in Cells

As shown in Chapter 1.4, the kinase inactivating mutations of ErbB3 have shown little
effect on ligand induced ErbB autophosphorylation in BaF3 cells or Akt activation in
CHO cells, arguing that kinase activity of ErbB3 does not directly contribute to these
cellular signaling. However, it is still possible that ErbB3 kinase participate in other
signaling events that are not investigated in our cellular studies. One common strategy to
study the cellular signaling of kinases is to use specific kinase inhibitors. However, this
standard approach is impossible for our study since there is no ErbB3 kinase-specific
inhibitor currently available. We have also discussed in Chapter 1 about the possibility
that ErbB3 kinase may have distinct substrates other than the phosphorylation sites
examined in our study. Therefore, we need to look for potential substrates of ErbB3
kinase in cells. However, historically it has been very difficult to track direct substrate of
kinases in a cellular content.
To overcome these problems, the Shokat lab at U.C.S.F has developed a chemical
genetic approach using a group of specific ATP analogs, which cannot be effectively
accommodated by wildtype kinases, as either inhibitors (bumped inhibitors) or substrate
phosphate donors (bumped ATPs) for rationally engineered kinases (Figure 1) (Elphick,
Lee et al. 2007). Removing the side chain of a ‗gatekeeper‘ residue in the ATP binding
site of kinase creates extra space for the engineered kinase to bind these ATP analogs
(without disrupting intrinsic kinase activity). The engineered kinase is therefore called
analog-sensitive (AS) kinase. There are two classes of ATP analogs: (1) ‗bumped ATPs‘,
in which a bulky group is attached onto the N6 position of ATP, that can be used as ATP
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substrate by AS kinases; and (2) membrane-permeable ‗bumped inhibitors‘, in which
bulky groups are attached onto adenine scaffold, that serve as specific inhibitors for AS
kinases. Ideally, these bumped ATP/bumped inhibitors will only affect the function of
engineered kinases with analog-sensitive mutation, but not the activity of corresponding
wildtype kinase (Figure 1).
With this chemical genetic approach, I have attempted to dissect the cellular
signaling role of ErbB3 using bumped ATP/bumped inhibitors on analog-sensitive ErbB3
mutant (and using wildtype ErbB3 as a control group). As shown in the main text, full
length ErbB3 with analog sensitive mutation (T768G) fully retains signaling ability of
ligand induced ErbB autophosphorylation (in BaF3 cells, Figure 1.10A) and Akt
activation (in CHO cells, Figure 1.11), suggesting that its signaling function is intact.
Unfortunately, the analog-sensitive mutation (T768G) causes aggregation of recombinant
protein of ErbB3 kinase overexpressed in sf9 cells, which makes it difficult to directly
characterize the effect of bumped ATP/bumped inhibitors on analog sensitive ErbB3
kinase mutant in vitro. To circumvent this problem, homologous EGFR kinase has been
used as a model system to validate this approach since the equivalent analog-sensitive
mutation (T766G) is well tolerated in recombinant EGFR intracellular protein and does
not affect its solubility/activity. The preliminary studies with EGFR have yielded some
encouraging results, and warrant further investigation of ErbB signaling using this
approach.
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Figure 1: Diagram of the chemical genetic approach to study cellular signaling of kinases. (A) Due to the
steric hindrance of ATP binding pockets, wildtype kinases cannot bind effectively to ‗bumped inhibitors‘ or
‗bumped ATPs‘. (B) Mutating the gatekeeper residue in the kinase of interest results in a analog-sensitive
kinase that can effectively utilize the ‗bumped ATPs‘ or bind to ‗bumped inhibitors‘ with high affinity.
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2.1 Using Bumped Inhibitors to Selectively Inhibit Cellular Signaling by Analogsensitive ErbB Mutant.
Due to the lack of inhibitors specific for wildtype ErbB3 kinase, we investigated whether
bumped inhibitors can serve as specific inhibitors for analog-sensitive (T768G) ErbB3 in
cellular studies. We have obtained four membrane-permeable bumped inhibitors from the
Shokat lab (1-NA-PP1, 1-NM-PP1, 2-NA-PP1 and 2-NM-PP1). Their chemical structures
are shown in Figure 2A. The ideal bumped inhibitor shall selectively inhibit analogsensitive kinase mutant in the assay and at the same time have minimal influence on the
activity of wildtype kinase. Since ErbB3 signaling requires other ErbB kinases in the
heterodimer, a successful candidate inhibitor for my study shall not inhibit any wildtype
ErbB kinases (not only ErbB3 kinase).
Thus, before applying the bumped inhibitors in the cellular assays, we need to
first make sure that (1) bumped inhibitors only binds to analog-sensitive ErbB3 kinase
but not wildtype ErbB3 kinase; and (2) bumped inhibitors do not compromise the kinase
activity of other ErbB family RTKs (especially ErbB2) that form heterodimer with ErbB3.
Unfortunately, recombinant proteins of either wildtype ErbB2 kinase domain or T768Gmutated ErbB3 kinase domain form total aggregates when overexpressed in sf9 cells,
which prevents the characterization of their binding to bumped inhibitors in vitro.
Therefore, we cannot directly test whether both conditions (1) and (2) are fully satisfied
in our chemical genetic approach. On the other hand, both wildtype and analog-sensitive
(T766G) EGFR kinase domains can be easily purified as recombinant protein. Therefore,
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we decided to use EGFR kinase as a model for testing the effect of bumped inhibitors on
ErbB family kinases.
Using an in vitro radioactive [γ-32P]ATP kinase assay, we have investigated
whether the bumped inhibitors can selectively inhibit analog-sensitive EGFR kinase but
not wildtype EGFR kinase. 10µM of each inhibitor is used in the kinase assay with
purified recombinant EGFR kinases and the kinase activity is monitored as incorporation
of 32P into substrates (Figure 2B). The results suggest that, while all four inhibitors are
able to inhibit analog-sensitive (T766G) EGFR kinase, three of them are also strong
inhibitor for wildtype EGFR kinase. Only 2-NM-PP1 meets our criteria of a selective
inhibitor for analog sensitive ErbB kinase, and it will be used in our subsequent cellular
assays.
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Figure 2: Inhibitory effect of bumped inhibitors on EGFR kinases. (A) Chemical structures of bumped
inhibitors (Bishop, Kung et al. 1999). (B) Selectivity of bumped inhibitors to EGFR kinase (wildtype or
analog-sensitive). In the kinase assays, 0.5 µM EGFR kinase domain (wildtype or T766G) is incubated
with 100 µM ATP, ~1 µCi [γ-32P]ATP, 200 µM poly GluTyr peptide substrate, 5 mM MgCl2 and 10 µM
indicated inhibitor or DMSO control (-) for 5 minutes at room temperature. The reactions are stopped with
100mM EDTA and spotted onto nitrocellulose paper for washing and scintillation counting to measure the
incorporation of 32P. A no kinase control is also included. The measurements shown are the average values
from duplicated experiments and the error bar indicates the high and low values. A maximum of <7% of
total 32P is incorporated in the assays.

Next, we applied 2-NM-PP1 on transfected CHO cells expressing either wildtype
or analog-sensitive EGFR protein, and showed that this bumped inhibitor can selectively
inhibit the kinase activity of analog-sensitive EGFR in CHO cells (Figure 3). Ligandinduced autophosphorylation of analog-sensitive (T766G) EGFR was nearly abolished at
the presence of 3 µM 2-NM-PP1. On the other hand, the activity of wildtype EGFR was
not affected by 2-NM-PP1 until the concentration of the inhibitor was raised by 10 fold
(30 µM). Therefore, 2-NM-PP1 can be used as a selective inhibitor for analog-sensitive
EGFR at low micromolar concentration.
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Figure 3: 2-NM-PP1 preferentially inhibits cellular signaling by EGFR with analog-sensitive mutation.
CHO cells were grown in 12 well dishes, transiently transfected with pcDNA3.1-EGFR (full-length,
wildtype or T766G) constructs and serum-starved overnight. 48 hours post transfection, 2NM-PP1 was
added to each well with indicated final concentrations from a 10 mM stock solution (in DMSO) and cells
were maintained in 37 ºC for one additional hour. Afterwards, cells were placed on ice and stimulated with
100 ng/ml final concentration of EGF. Cells were then washed with PBS and lysed in RIPA buffer and
subjected to western blotting. PhosphoEGFR was detected by pY20 anti-phosphotyrosine antibody; total
EGFR were monitored by anti-EGFR Ab12 (labvision) and anti-Actin blots were used as loading controls.
Experiments were performed in duplicates.
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We then applied the 2NM-PP1 in our cellular assay for ErbB3 kinase, and
investigated whether the bumped inhibitor can affect signaling by analog-sensitive ErbB3
mutant. In BaF3 cells co-expressing ErbB2/ErbB3, adding 2NM-PP1 resulted in
decreased level of ligand-induced ErbB autophosphorylation in both cell lines carrying
wildtype or T768G-mutated ErbB3 (Figure 4A). The decrease of ErbB
autophosphorylation in wildtype ErbB2/ErbB3 applied with 2NM-PP1 suggested the
presence of off-target effect. Although, comparing to cells carrying wildtype ErbB3, the
decrease of autophosphorylation seemed more prominent in cells carrying T768Gmutated ErbB3, such effect is not statistically significant in our subsequent repeats.
Therefore, we cannot conclude whether the cellular effect we observed is due to
inhibition of ErbB3 kinase by 2-NM-PP1 or its off-target effect. Similarly, in CHO cells
expressing wildtype or T768G-mutated ErbB3, no apparent effect is observed for ligandinduced Akt activation when 2NM-PP1 is applied (Figure 4B). It is too early to draw any
conclusion from these results, since (1) we do not know whether 2-NM-PP1 binds
preferentially to analog-sensitive ErbB3 and (2) we used the same cellular assays as in
Chapter 1.4, in which the kinase-compromised ErbB3 mutants showed little effect.
However, this bumped inhibitor approach is still promising for a more comprehensive
study of ErbB3 kinase signaling using a proteomic approach, such as SILAC, at the
absence of specific ErbB3 inhibitors.
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Figure 4: Application of 2-NM-PP1 on cellular signaling of analog-sensitive ErbB3 mutant. (A) BaF3 cells
stably co-expressing ErbB2 wildtype and either ErbB3 wildtype or analog-sensitive (T768G) ErbB3 mutant
were serum-starved for 4 hours, then further incubated with 8 µM 2-NM-PP1 or DMSO control for 2 hours.
Cells were then resuspended in PBS and stimulated with Nrg1β on ice for 10 minutes. (B) CHO cells were
transiently transfected with pcDNA plasmids containing either ErbB3 wildtype or analog-sensitive (T768G)
ErbB3 mutant. 24 hours after transfection, CHO cells were serum-starved overnight, and then incubated
with indicated amount of 2-NM-PP1 for 1 hour before stimulated with 5 ng/ml of Nrg1β for 20 minutes at
37 ºC. Samples were prepared in the same way as described in Experimental Procedures.
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2.2 Using Bumped ATPs as Preferred Substrates for Analog-sensitive ErbB Kinase
Bumped ATPs have been used in multiple studies to identify the direct physiologic
substrate of the engineered analog-sensitive kinase as well as study substrate specificity
in cells (Elphick, Lee et al. 2007). Briefly, a 32P-label can be incorporated into the γ
phosphate group of bumped ATP. Then the 32P label can be used to trace the substrates
that are directly phosphorylated by this analog sensitive kinase in cells, since (at least in
an ideal situation) only the engineered analog-sensitive kinase, but not the wildtype
kinases, can utilize the 32P labeled bumped ATP as substrate. As a proof of principle, we
first used this approach to study EGFR kinase (as it is ~1000 fold more active than ErbB3
kinase). The goal is to investigate whether 32P labeled bumped ATP can be used to
identify the physiological substrate of EGFR kinase in cells. This study can be broken
down into four stages:
1) Generation of bumped ATP
2) Test whether analog-sensitive EGFR kinase can effectively utilize bumped ATP
3) Development of membrane permeabilization method that allows bumped ATP to pass
through plasma membrane and enter cytosol
4) Using bumped ATP to trace protein phosphorylation mediated directly by EGFR
1) Generation of γ-32P labeled bumped ATP ([γ-32P] N6-Bn-ATP)
Due to the relative short half life (~14 days) of 32P, γ-32P labeled bumped ATP needs to
be generated shortly before the cellular assay. This is achieved by transferring γ-32P
phosphate from fresh [γ-32P]ATP onto bumped-ADP using purified recombinant yeast
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nucleoside diphosphate kinase (yNDPK) (Figure 5A). Briefly, the γ-32P phosphate is first
transferred from ATP to a histidine side chain on yNDPK protein to form an unstable
phosphate-protein intermediate and ADP. ADP can be washed away and bumped ADP is
then added to take the γ-32P phosphate from yNDPK to form [γ-32P]bumped-ATP. Using
this method, we have generated [γ-32P] N6-Benzyl-ATP ([γ-32P] N6-Bn-ATP), the most
commonly used bumped ATP, with a protocol adapted from (Elphick et al. ACS
Chemical Biology 2007). The radioactivity generated by each step is monitored by
scintillation counter (Figure 5B).


Immobilize 0.1mg purified, recombinant yNDPK (6x His tagged) with 20ul NiNTA
beads in 1ml resuspension buffer (RSB: 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5%
Glycerol), and wash once with RSB.



Incubate the beads with 50uCi 32P-ATP in 1ml RSB, and continue mixing on nutator
for 5 min.



Spin down NiNTA beads at 500 g, remove the solution. (Figure 5B column 1 shows
the remaining [γ-32P]ATP in solution after incubation with yNDPK.)



Wash three times with RSB + 1x phosphate (10 mM Na2HPO4, 2 mM KH2PO4).
(Figure 5B column 2-4)



Wash once with RSB + 1x phosphate + 10 µM adenosine. (Figure 5B column 5)



Wash twice with RSB without phosphate. (Figure 5B column 6)



Incubate with 5nmol of N6-Bn-ADP in 200ul RSB + 10mM MgCl2 for 5 min. Spin
down the beads and transfer the solution to another tube. The solution contains the
newly generated [γ-32P] N6-Bn-ATP, which has incorporated ~60% of the initial 32P.
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(Figure 5B column 7 shows the radioactivity of [γ-32P]N6-Bn-ATP, column 8 shows
the remaining 32P left on NiNTA beads)


Make aliquots and freeze in -20 ˚C.

Figure 5 Generation of radioactive bumped ATP. (A) Diagram showing the transfer of [γ-32P] from ATP to
bumped ATP using yNDPK (adapted from (Elphick, Lee et al. 2007)). (B) Tracking the radioactive signal
generated in each step during a typical preparation. 1% of the solution from each step is used to monitor its
radioactivity using scintillation counter. Numbers are averaged from duplicated measurements.
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2) Test whether analog-sensitive EGFR kinase can effectively utilize bumped ATP
EGFR kinase is used as a model to investigate whether the chemical genetic approach
with bumped ATP can be applied to ErbB kinases. In an in vitro radioactive kinase assay,
both wildtype and T766G-mutated EGFR kinase can effectively utilize [γ-32P]ATP as
substrate, whereas only analog-sensitive (T766G) EGFR kinase can utilize [γ-32P]N6Bn-ATP (Figure 6). Based on the readings from scintillation counter, we conclude that
T766G-mutated EGFR kinase utilizes [γ-32P]N6-Bn-ATP >100 times more efficiently
than wildtype EGFR kinase.

Figure 6: Bumped ATP (N6-Bn-ATP) can only be utilized by analog sensitive EGFR kinase but not
wildtype EGFR kinase. In the kinase assays, 1 µM purified recombinant EGFR kinase domain (wildtype or
T766G) is incubated with 100 µM ATP, ~1 µCi [γ-32P]ATP (or [γ-32P]N6-Bn-ATP), 200 µM poly GluTyr
peptide substrate and 5 mM MgCl2 for 5 minutes at room temperature. The reactions are stopped with
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100mM EDTA and spotted onto nitrocellulose paper for washing and scintillation counting to measure the
incorporation of 32P. A no kinase control is also included. The measurements shown are the average values
from duplicated experiments and the error bars represent one standard deviation. A maximal of 20% of
total 32P is incorporated in the assays.

3) Development of membrane permeabilization method that allows bumped ATP to pass
through plasma membrane and enter into cytosol.
Permeabilization of cell membrane is needed for the negatively charged [γ-32P]N6-BnATP to enter into cytosol and be utilized by kinases. At the same time, the disruption of
cell membrane shall not interfere with ligand-induced ErbB dimerization/activation. We
have shown that digitonin-permeabilization can meet such requirements, as demonstrated
in both ErbB3 activation in T47D cells (Figure 7A) and EGFR activation in CHO cells
(Figure 7B). In these experiments, cell pellets were mixed with equal volume of PBS (for
intact cells) or cell lysis buffer (CLB, for permeabilizaed cells) containing 10 mM Tris
pH 7.4, 150mM NaCl, protease inhibitors (1 mM PMSF, 10 µM leupeptin and 10 µM
aprotinin), phosphatase inhibitors (25 mM NaF, 5 mM Na2MoO4 and 0.2 mM Na3VO4)
and varying amount of digitonin (CALBIOCHEM Cat# 300410). Cell permeabilization
was then verified by trypan blue staining and followed with ligand stimulation
experiments. Reactions were stopped with 100 mM EDTA pH 8.0, and samples were
prepared for SDS-PAGE and Western blotting.
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Figure 7 Permeabilization of cell membrane with digitonin does not affect ligand induced ErbB signaling.
(A) Parental T47D cells were serum-starved overnight, detached from flasks with PBS+EDTA, washed in
PBS, and then resuspended in cold PBS (for intact cells) or CLB buffer containing 0.05% (m/v) digitonin
(for permeabilized cells). The volume of the resuspension buffer is equal to the volume of the cell pellet.
Then 5mM MgCl2 and optional 1 mM ATP were added to permeabilized cells. Cells were then stimulated
with Nrg1β (40 ng/ml) for 5 minutes on ice and processed for Western blotting. (B) CHO cells transiently
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transfected with EGFR (wildtype or T766G) were serum-starved overnight, washed and resuspended in
cold PBS (for intact cells) or CLB buffer containing 0.01% (m/v) digitonin, 5mM MgCl 2 and 0.5 mM ATP.
Cells were then stimulated with EGF (100 ng/ml) for 5 minutes on ice (for intact cells) or 3 minutes at
room temperature (for permeabilized cells) and processed for Western blotting.

4) Using bumped ATP to trace protein phosphorylation mediated directly by EGFR
We have applied [γ-32P]N6-Bn-ATP to permeabilized cells expressing wildtype or
analog-sensitive (T766G) EGFR mutant and, after ligand stimulation experiement, used a
radioactive phospho-image gel to look for protein substrates that carried the 32P
phosphate. Unfortunately, we could not identify any unique (or prefered) protein
substrates in cells expressing T766G-mutated EGFR yet, due to the high background 32P
signals (many non-specifically labeled bands on the SDS-PAGE gel) in the assay. The
main reasons for the high background signal are (a) many endogenous wildtype kinases
can still utilize the bumped ATP as substrate at appreciable rates and (b) the γ-32P
phosphate on [γ-32P]N6-Bn-ATP can be rapidly transferred onto other nucleotide
diphosphate (NDPs) by endogenous NDPK in cells, which can then be effectively
utilized by wildtype kinases.
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